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 Vibrio cholerae produces several virulence factors to establish infection, 
most of which are regulated by the ToxR regulatory pathway. The direct activator 
of virulence gene transcription is the protein ToxT.   TarA is a ToxT-activated 
small, regulatory RNA (sRNA) that is conserved throughout toxigenic V. cholerae 
strains. It lacks open reading frames and has a putative binding site for the 
bacterial regulatory protein Hfq, which is implicated in the function of several 
sRNAs. Based on these observations, we hypothesized that TarA has a 
regulatory function. Microarray analysis of a tarA mutant and wild type V. 
cholerae revealed increased RNA for ptsG, which encodes the major glucose 
transporter. This result was confirmed, and we further demonstrated decreased 
ptsG transcript levels in response to TarA induction. Additionally, V. cholerae 
overexpressing TarA take up less glucose and grow poorly in glucose-containing 
media. A working hypothesis is that TarA is stabilized by the protein Hfq and 
regulates ptsG by base-pairing with the 5ʼ untranslated region of the ptsG 
transcript, which targets the transcript for degradation by RNase E. Analysis by 
electrophoretic mobility shift assays demonstrated that TarA binds the ptsG 
leader sequence in vitro. Additionally, a V. cholerae mutant lacking hfq has lower 
steady state levels of TarA, presumably due to more rapid turnover in the 
	   xii	  
absence of its interaction partner.  Mutational analysis suggests that TarA 
possesses at least two redundant Hfq binding sites. 
 TarA appears to regulate several metabolic genes in addition to ptsG, 
including the sialic acid catabolism genes found at the nan locus.  In the absence 
of TarA, nan transcripts are diminished, suggesting that TarA activates these 
genes.  TarA may work in conjunction with the repressor protein NanR to 
precisely control expression of these genes.  These data lead to the hypothesis 
that TarA regulates V. cholerae adaptation to the changing nutrient conditions it 











Cholera: past and present 
 Cholera is a waterborne gastrointestinal illness that has afflicted humans 
throughout recorded history. This disease is characterized by massive fluid loss 
through secretory diarrhea, which contains high levels of mucus and resembles 
rice water. If untreated, the severe dehydration caused by cholera is often fatal.  
While cases of cholera have been documented since 500 to 400 B.C.E., these 
were mainly limited to sporadic outbreaks in isolated areas prior to the early 19th 
century (Lacey, 1995).  Cholera is endemic to the Indian subcontinent and has 
spread worldwide to cause seven pandemics.  The exact dates of the pandemics 
are somewhat controversial; in many cases, historical records are incomplete 
and tracking down the first and last case of cholera in a particular pandemic is 







































It is widely accepted that the first cholera pandemic started in 1817 with 
the advent of international trade (Sack et al., 2004). After a season of unusually 
heavy rainfall and massive flooding in India, cholera sickened hundreds of 
thousands, with a focus in the province of Bengal, which included the city of 
Calcutta (Kolkata).  British soldiers stationed in this area fell victim to the illness 
and subsequently transmitted it to Nepalese soldiers against whom they were 
fighting.  From there, the disease reached the countries of China, Malaysia, and 
Japan via merchant ships.  This first pandemic lasted until 1824, when an 
abnormally cold winter halted spread of the disease (Pollitzer, 1954).  
 The second pandemic, spanning from 1829 to 1851, also originated in 
India.  In this instance, cholera was spread by Polish and Russian soldiers who 
carried the disease into their home countries.  By 1831, cholera had reached 
Austria and England, and the following year, Ireland, France, and Belgium all 
experienced epidemics. In the same year, an outbreak of cholera in Mecca 
sickened thousands of pilgrims, who brought the illness back to Syria, Palestine, 
and Egypt.  Increased travel and immigration further facilitated explosion of the 
disease, which reached Scandinavia and crossed the Atlantic Ocean in 1832, 
entering North America through the cities of Quebec and New York (Pollitzer, 
1954). In the course of the second pandemic, cholera reached every continent 




 After a brief respite, pandemic cholera returned in 1852, following a severe 
outbreak of the disease in India.  The first years of this pandemic were 
disastrous, with the United States, Canada, Mexico, the West Indies, England, 
France, Greece, and Turkey being the most hard-hit countries.  The spread of 
cholera to the latter two was largely blamed on the Crimean War (1853 to 1856), 
as infected troops traveled from southern France to these countries (Pollitzer, 
1954).  Meanwhile, in England, an outbreak of disease in a neighborhood of 
London led John Snow, a physician, to link the transmission of cholera with 
ingestion of contaminated water (Snow, 1855), a pioneering observation in public 
health epidemiology.  This important discovery had lasting effects; from that point 
on, England suffered far fewer cholera cases than it had in the past, even as the 
disease was repeatedly brought into the country.  The causative agent of cholera, 
the Gram-negative bacterium Vibrio cholerae, was isolated in the same year by 
Filippo Pacini, though Robert Koch is widely credited with making this 
breakthrough in 1884 (Lacey, 1995). Within the next few years, the number of 
cases worldwide dwindled, and the third pandemic was largely over by 1859 
(Pollitzer, 1954). 
 The fourth pandemic, lasting from 1863 until approximately 1875, marked 
a shift in the routes of transmission of cholera.  New trade routes had been 
established at this time, providing a means for the disease to be spread even 
more efficiently. In particular, 1865 was an especially important year, as it was a 
jubilee year in Mecca, where scores of pilgrims gathered.  An outbreak in Mecca 
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led to massive numbers of cases, and many of these infected people carried 
cholera to their homelands of Egypt, Syria, Palestine, Mesopotamia, and others.  
The spread of disease to Egypt was especially fateful, as cholera took hold in 
Alexandria, a major shipping center on the Mediterranean Sea.  This facilitated 
transmission to other port cities and re-introduced cholera to Europe, where it 
ravaged several countries, including Austria, Hungary, Germany, the 
Netherlands, Belgium, and Russia.  Later in the decade, the disease gripped 
northern and eastern Africa, concomitant with the rise of Mozambique and 
Zanzibar as shipping centers (Pollitzer, 1954).   
 The fourth pandemic also affected North America, reaching New York City 
by sea in 1865 or 1866.  It spread rapidly once there, traveling by the ever-
expanding rail system and reaching as far west as Kansas. In response to the 
rampant spread of the disease in New York, the nationʼs first Board of Health 
was founded in 1866 (Duffy, 1971).  While some measure of disease control was 
taking place in the United States, cholera was spreading deeper into South 
America at that time, reaching Argentina, Peru, Brazil, and Uruguay.  From a 
global standpoint, the disease was still very much a problem, even as the fourth 
pandemic waned in the 1870ʼs. 
 In 1884, as the fifth pandemic raged on, Robert Koch conclusively linked 
the cause of cholera to infection with the bacterium V. cholerae (Koch, 1884).  
This discovery did not immediately lead to preventative measures, as France, 
Italy, and Spain saw epidemics throughout the mid-1880ʼs. Of note, cholera was 
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re-introduced to both England and New York City several times during this 
period, but there were no new outbreaks due to proper quarantine techniques 
and improved water sanitation.  Other areas of the world were not so lucky; the 
fifth pandemic claimed hundreds of thousands more lives and persisted until 
1896 (Pollitzer, 1954).  
 As the twentieth century began, severe outbreaks of cholera in Calcutta 
and Bombay sparked the beginning of the sixth pandemic, which lasted until 
approximately 1923.  This pandemic was marked by increased spread of the 
disease due to World War I and saw massive numbers of cases in Europe and 
Russia, with a peak of infection in 1921. In the following years, fewer infections 
were noted, with Europe being largely free of cholera after 1925 (Pollitzer, 1954). 
    The seventh pandemic, according to most sources, began in 1961 and 
continues today (WHO, 2011).  This pandemic differed from the first six in several 
ways.  While prior pandemics had originated in severe outbreaks in India, the 
seventh began in Indonesia and spread from there. Additionally, in contrast to the 
previous six pandemics, which were caused by V. cholerae of the classical 
biotype, the bacteria responsible for the current pandemic belong to the El Tor 
biotype, which is generally considered less virulent than its classical relatives.  
Nonetheless, cholera claimed hundreds of thousands of lives as it spread 
through Asia, Europe, and Africa, eventually reaching Peru by freighter in 1991.  
In the late 1980ʼs, studies by the Environmental Protection Agency linking 
chlorination byproducts with cancer had led Peruvian officials to stop chlorinating 
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some of the wells in Lima. Thus, when wastewater contaminated with V. cholerae 
entered the main water supply, the disease spread easily and made this 
epidemic especially devastating (Anderson, 1991).  Recent studies have 
suggested that while adequate chlorination of the water supply would not have 
prevented the epidemic entirely, it would have saved thousands of lives (Tickner 
& Gouveia-Vigeant, 2005).  
 While cholera remains a severe public health problem, it is now limited to 
developing countries with poor infrastructure, especially those that have recently 
experienced military conflicts and natural disasters.  Cholera remains endemic in 
India and Bangladesh, and cases generally appear in waves centered around the 
monsoon season. These waves of cases are often limited by the presence of 
bacteriophages, or bacterial viruses, that prey on V. cholerae (Faruque et al., 
2005).   
In the last few years alone, Zimbabwe, Iraq, Afghanistan, and Sudan, among 
others, have seen deadly epidemics of cholera (WHO, 2011).  Most recently, 
Haiti, a country that had not recorded cases of cholera for more than a century, 
suffered a severe outbreak of disease following a devastating earthquake in 
January 2010 (Piarroux et al., 2011).  Sequence analysis of bacteria isolated 
from patients indicated that the disease had likely been imported into Haiti by 
Nepalese troops who arrived as part of post-earthquake humanitarian relief 
efforts (Chin et al., 2011) and had spread through improperly treated drinking 
water.  While the intensity of the epidemic has waned somewhat, it is expected 
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that the disease will linger in Haiti until water sanitation can be improved (Butler, 
2011).    
 
Symptoms and treatment 
 Cholera is characterized by the profuse watery diarrhea induced by 
secretion of cholera toxin into the intestinal lumen (Figure 1.2).  This diarrhea, 
while painless and non-inflammatory, can lead to severe dehydration and death 
in a matter of hours, with patients losing up to a liter of fluid an hour.  Vomiting is 
less common but does occur, contributing to the observed dehydration.  In the 
absence of treatment, indicators of severe dehydration, such as sunken eyes, 
loss of skin elasticity, and barely detectable blood pressure manifest within 
hours.  Untreated patients can lose up to ten percent of their body weight within 
24 hours of the first symptoms, the period in which most deaths from cholera 
occur (Sack et al., 2004).  In many clinics, cholera cots are utilized, which allow 








Figure 1.2. Photograph of rice water stool collected from a cholera 





 Currently, treatment of cholera is quite effective and focuses on 
administration of Oral Rehydration Therapy, or ORT, the goal of which is to 
replace the massive amount of fluid lost by cholera patients. The composition of 
the fluid given is important, as patients lose both electrolytes and water to the 
secretory diarrhea of cholera; if only water is given, the patient will suffer severe 
hyponatremia. As glucose and sodium are co-transported across the intestinal 
epithelium, sodium absorption by the patient is much more efficient if glucose is 
present in the solution. While the most commonly used Oral Rehydration Salts 
(ORS) mixture refers to specific quantities of glucose and salts, the term ORT 
can be used for most liquids given to a cholera patient.   
 The idea of replacing fluids lost to diarrhea is not new; in fact, it dates back 
3000 years to the Indian physician Sushruta, who prescribed a mixture of water, 
rock salt and molasses as a treatment for diarrhea (da Cunha Ferreira & Cash, 
1990). While ORT in some form, be it rice water, coconut juice, carrot soup, or 
another fluid, has been used to treat cholera in India for the past three millennia, 
this development did not catch on in other countries until the mid-1900ʼs (da 
Cunha Ferreira & Cash, 1990).  The formulation most commonly used today 
(reduced osmolarity ORS) consists of 75 millimolar (mM) sodium chloride, 75 mM 
glucose, 20 mM potassium chloride, and 10 mM trisodium citrate; this specific 
combination has been most efficacious at treating severe dehydration (WHO, 
2006).  In the past, intravenous fluid replacement has also been used to treat 
cholera, while today it is only used for patients too ill to drink.   
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In most cases of cholera, antibiotics are ineffective because the disease 
symptoms are caused by cholera toxin, which is rapidly produced upon infection.  
Antibiotics target V. cholerae itself and by the time they are administered, high 
levels of toxin production have already occurred.  Similarly, antibiotic treatment 
does not lessen transmission of disease, as the onset of diarrhea has already 
occurred, triggering shedding of the bacteria into wastewater.  As such, 
antibiotics are now rarely used to treat cholera, and generally only lessen the 
severity and duration of disease in some cases (Lindenbaum et al., 1967). 
 
Cholera vaccines 
 While the discovery of V. cholerae as the causative agent of cholera 
prompted research into pathogenesis of the disease, progress was quite slow at 
the outset.  In fact, it was not until 1959 that the transmission of cholera via the 
fecal-oral route was proposed by S.N. De (De, 1959).  Previously, investigators 
had tried injecting V. cholerae into animals via virtually every other route and had 
not been able to recapitulate disease symptoms. De observed massive fluid 
accumulation after injecting V. cholerae culture filtrates into a ligated rabbit ileal 
loop.  He proposed that this bacteria “multipl(ies) in the small bowel and 
produce(s) an exotoxin which acts upon the mucosal cells of the small bowel, 
causing them to secrete large quantities of isotonic fluid… and the result is a 
watery isotonic diarrhea”(De, 1959).  Prior to Deʼs discovery, immunization 
studies focused on injectable vaccines with limited success.  The most widely 
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used of these preparations was a killed whole-cell vaccine developed in the late 
1800ʼs.  This fairly expensive vaccine was extensively tested in Bangladeshi 
children in the 1960ʼs and was found to provide limited protection while causing 
undesirable side effects (Mosley et al., 1972). Given its poor efficacy and side 
effects, the vaccine is not recommended by the WHO.   
 Recently, focus has shifted to oral vaccination strategies, which have been 
more successful. Vaccines given by this route are especially valuable because 
they present antigen to the immune system in the same manner that an infection 
would. While both live attenuated vaccines and killed whole-cell preparations 
have been developed, the latter have been more fruitful, with greater protection 
and fewer side effects (for review see (Bishop & Camilli, 2011)).  Several trials of 
oral live attenuated vaccines have been conducted in the US and abroad; one of 
the largest studies tested the strain CVD 103-HgR on nearly 70,000 volunteers in 
Indonesia.  This trial was largely considered a failure because while only very few 
subjects developed cholera, the number of cholera cases were similar between 
the placebo and vaccine groups (Richie et al., 2000).  Other live attenuated 
vaccine strains that have been developed, such as Peru-3, have produced 
reactogenic diarrhea in patients (Taylor et al., 1994).  Recent work with the infant 
rabbit model of cholera disease has pinpointed the presence of flagellins as the 
cause of this inflammatory side effect (Rui et al., 2010).  
Dukoral, an oral vaccine consisting of recombinant cholera toxin B 
subunits and killed V. cholerae of the Ogawa and Inaba serotypes and classical 
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and El Tor biotypes, was developed in the 1980ʼs.  While relatively expensive 
and requiring two doses (three doses for young children), this vaccine was shown 
to be quite effective, providing 85% protection six months after administration in 
one study (Clemens et al., 1986).  Dukoral was licensed in 1991 and has been 
used in refugee camps with success (Legros et al., 1999).  Another oral vaccine, 
Shanchol, has recently been approved for use by the WHO.  Shanchol lacks the 
recombinant cholera toxin B subunit, making it cheaper than Dukoral and thus 
more attractive for use in developing countries.  While Shanchol also requires 
two doses, a third dose is not required for children under the age of six (WHO, 
2010).  It is a killed whole-cell formulation containing V. cholerae of both the O1 
and O139 serotypes. 
 Though there are currently two viable vaccines on the market, research in 
this area continues in hopes of creating a preparation that demonstrates good 
protection in children, is cost-effective, and is easy to administer to large 
populations.  Studies utilizing outer membrane vesicles from V. cholerae have 
shown particular promise, with these preparations providing immunity to neonatal 
mice when given to pregnant mice (Bishop & Camilli, 2011).  Additionally, the 
recent re-emergence of an infant rabbit model of disease has provided an 
important tool for testing of new vaccine candidates (Rui et al., 2010).  This 
model was first used extensively in the 1950ʼs and 60ʼs and has become more 
favored in recent years, as it recapitulates cholera symptoms well in a small 
animal (Finkelstein et al., 1964, Dutta & Habbu, 1955).  The field of cholera 
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vaccine research is thus still very active, with many recent and exciting 
developments towards a safe, effective vaccine. 
 
Vibrio cholerae biotypes and serotypes 
To date, over 200 different serotypes of V. cholerae have been isolated, 
but only two of these (O1 and O139) have been found to cause epidemic 
disease.  The serotypes are classified based on the specific O-antigen found on 
the lipopolysaccharide (LPS), which is a component of the bacterial outer 
membrane.  Within the O1 serotype, there are two subtypes, Ogawa and Inaba, 
and two biotypes, classical and El Tor.  The Ogawa and Inaba isolates are 
distinguished by genetic differences in one specific part of the O antigen, while 
the two biotypes differ at both genetic and phenotypic levels. Classical strains of 
V. cholerae caused the first six pandemics of cholera; the current pandemic 
features an El Tor strain. While these distinctions are helpful in the laboratory, 
recent research has suggested that there is significant genetic fluidity between 
the two biotypes of V. cholerae.  In fact, hybrid, or “El Tor variant” strains have 
been isolated from cholera patients in Bangladesh, Haiti, India, Thailand, and 
Malaysia, among other countries (Son et al., 2011, Goel et al., 2011, Na-Ubol et 
al., 2011, Ang et al., 2010).  These strains are constantly evolving through 
horizontal gene transfer, leading to a diverse population of bacteria in the 
environment.  One mechanism of gene acquisition in the environment may be 
natural competence, which is induced by chitin, a common component of marine 
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species with which V. cholerae associates in nature (Meibom et al., 2005).   The 
most recently identified genetic elements, VSP-I and VSP-II, or Vibrio seventh 
pandemic islands I and II, were discovered in the last decade (Dziejman et al., 
2002) and contain several yet-to-be-characterized genes that may have roles in 
the pathogenesis of these strains.  These regions, specifically VSP-II, are highly 
variable and appear to undergo frequent genetic rearrangements (Taviani et al., 
2010).  In sum, delineation of V. cholerae into two distinct biotypes may soon be, 
if it is not already, an antiquated concept. 
 
 
Vibrio cholerae and mechanism of infection/transmission 
 Ingestion of water contaminated with V. cholerae gives the bacterium 
access to the gastrointestinal tract of the human host.  The infectious dose of V. 
cholerae is quite high because the majority of the organisms are killed by the 
acidity of the stomach.  Bacteria able to survive passage through this acidic 
environment reach the upper small intestine, where the production of toxin co-
regulated pilus (TCP) aids in adherence to the mucus layer (Herrington et al., 
1988).  While in close association with the intestinal mucosa, V. cholerae 
multiplies rapidly and secretes cholera toxin, which is responsible for the actual 
disease symptoms.  Cholera toxin (CT) is an AB5 toxin consisting of six subunits: 
an activity (A) subunit and five binding (B) subunits. Upon binding to GM1 
ganglioside on the surface of a host epithelial cell, the toxin is internalized by 
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receptor-mediated endocytosis and transported to the endoplasmic reticulum 
(ER) via retrograde transport.  In the ER, the catalytic (A1) portion of the A 
subunit is cleaved from the toxin complex; identified by the cell as a misfolded 
protein, it is then retrotranslocated to the cytosol for degradation (Tsai et al., 
2001). Usually, misfolded proteins in the cytosol are polyubiquitinated on lysine 
residues, triggering proteasomal degradation.  However, the CT A1 subunit 
contains few lysine residues and re-folds quickly in the cytosol, effectively 
avoiding this fate (Rodighiero et al., 2002).   
 Once free in the cytosol, cholera toxin ADP-ribosylates the s subunit of 
heterotrimeric G proteins, promoting adenylate cyclase activity, which leads to 
production of cyclic AMP (cAMP).  cAMP is a potent second messenger, and its 
buildup in epithelial cells sparks phosphorylation of the cystic fibrosis 
transmembrane conductance regulator (CFTR) and activation of chloride 
channels in the plasma membrane, among other events (De Haan & Hirst, 2004).  
This triggers high levels of chloride secretion and mucus shedding into the 
intestinal lumen; recent studies have provided evidence that V. cholerae 
associates with these secreted clumps of mucin (Ritchie et al., 2010). To 
maintain osmotic balance of the luminal fluid, water is also released, and the 
overwhelming abundance of fluid produces the secretory diarrhea experienced 
by cholera patients (De Haan & Hirst, 2004).  Shedding of this stool, which is rich 
in aggregates of mucin and mucin-associated bacteria, thus promotes 
transmission of V. cholerae to environmental reservoirs and new hosts. 
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 In order to efficiently colonize its host and promote spreading, V. cholerae 
tightly controls production of its virulence factors.  This regulatory cascade has 
been extensively reviewed in the literature (Matson et al., 2007).  Briefly, the 
inner membrane-bound proteins ToxR and TcpP coordinately activate 
transcription of the gene encoding ToxT, an AraC/XylS-like transcriptional 
regulator (Higgins et al., 1992).  ToxT then binds toxboxes (consensus binding 
sequences) upstream of virulence genes, activating transcription at these sites 
(Withey & DiRita, 2006).  Targets of ToxT include ctxAB, the tcp locus, and small 
regulatory RNAs (Richard et al., 2010, Bradley et al., 2011), among others.  V. 
cholerae strains lacking toxR, toxT, or tcpA display severe colonization defects in 
both suckling mice and human volunteers (Herrington et al., 1988, Taylor et al., 
1987, DiRita et al., 1991, Lee et al., 1999), while ctxA mutants are able to 
colonize both human and infant rabbit hosts but do not induce secretory diarrhea 
(Ryan et al., 2006, Rui et al., 2010).   
 A spatially and temporally regulated pattern of gene expression is crucial 
for successful V. cholerae infection and transmission. Studies using 
recombination-based in vivo expression technology (RIVET) have identified 
several genes induced during early and late infection of both human and infant 
mouse hosts that are required for colonization and disease spread, respectively 
(Merrell & Camilli, 2000, Lombardo et al., 2007, Schild et al., 2007).  As one 
might expect, gene products promoting colonization, such as toxin co-regulated 
pilus and the accessory colonization factors, are produced in the initial stages of 
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infection.  Later, once the bacteria have robustly colonized the bowel, the focus 
shifts to metabolic functions, such as storage of carbon in the form of glycogen 
(Bourassa & Camilli, 2009), in preparation for exit to the environment.  Vibrios 
freshly shed from the host are hyperinfectious compared to those grown in vitro, 
suggesting that the genes expressed in vivo help equip the bacterium not only to 
survive in nutrient-poor environmental reservoirs, but also to colonize its next 
host effectively (Merrell et al., 2002).  
 Regulation of carbon metabolism is also crucial for efficient colonization by 
V. cholerae. Like other bacteria, V. cholerae possesses an extensive 
phosphotransferase system (PTS) that allows it to grow on carbon sources such 
as glucose, fructose, mannitol, and chitobiose, among others.  These PTS 
systems are specific to certain sugars and are generally comprised of four 
proteins: enzymes I, IIA, and histidine protein (HPr), which are found in the 
cytoplasm, and enzyme IIBC, which is the membrane-bound component of the 
system.  The glucose-specific PTS system regulates biofilm formation in V. 
cholerae and has been well-studied (Houot et al., 2010a, Houot et al., 2010b, 
Houot & Watnick, 2008).  Briefly, upon presence of glucose in the media, 
phosphoenolpyruvate donates a phosphate group to EI.  Phosphorylated EI 
protein then transfers its phosphate group to the HPr, which in turn 
phosphorylates EIIA.  The glucose-specific EIIBC protein, called PtsG in V. 
cholerae, then takes up a glucose molecule and transports it through the 
membrane, converting it to glucose-6-phosphate with the phosphate donated by 
 19 
EIIA-P.  This results in the production of glucose-6-phosphate, which can be 
metabolized for energy.  Additionally, there is evidence that EI-P and EIIBC 
(PtsG) repress biofilm growth of V. cholerae by repressing transcription of the 
vps genes, thus promoting growth in the planktonic form.   
 In E. coli, ptsG is regulated by a small RNA, SgrS (Vanderpool & 
Gottesman, 2004).  Under conditions of glucose phosphate stress, in which 
glucose-6-phosphate has accumulated to toxic levels, the regulatory protein SgrR 
activates transcription of SgrS.  SgrS, a 227 nt small regulatory RNA, base-pairs 
with the leader sequence of the ptsG transcript, occluding the Shine-Dalgarno 
sequence and targeting the transcript for degradation by RNase E (Vanderpool & 
Gottesman, 2004).  This interaction is catalyzed by the small regulatory protein 
Hfq (Kawamoto et al., 2006).  SgrS also encodes a small peptide, SgrT, which 
relieves glucose phosphate stress as well, presumably by interacting with PtsG 
at the protein level (Wadler & Vanderpool, 2007). 
 
  
Small regulatory RNAs in Vibrio cholerae 
 Small regulatory RNAs (sRNAs), while recently discovered, have been 
increasingly recognized as important regulatory elements of prokaryotes and 
eukaryotes alike (Toledo-Arana et al., 2007, Liu & Camilli, 2010, Esteller, 2011).  
As in most types of bacteria, sRNAs are a key component of gene regulation in 
V. cholerae. These RNA molecules are generally between 75 and 400 
 20 
nucleotides in length and can act in cis or trans to regulate their targets at the 
RNA or protein level.  Thirteen of these RNAs have been characterized (Lenz et 
al., 2004, Lenz et al., 2005, Davis et al., 2005, Mey et al., 2005, Davis & Waldor, 
2007, Song et al., 2008, Richard et al., 2010, Bradley et al., 2011, Mustachio et 
al., 2012), while over 500 others have been predicted using bioinformatics and 
deep-sequencing approaches (Livny et al., 2005, Liu et al., 2009). Many sRNAs 
require the small hexameric protein Hfq for their function.  Hfq binds AU-rich 
sequences on both sRNAs and their targets and often serves to both stabilize the 
sRNA and to catalyze base-pairing between the two RNA molecules.  
 The first small regulatory RNAs found in V. cholerae were those involved 
in quorum sensing, Qrr1-4 and CsrB, CsrC, and CsrD.  The three Csr RNAs are 
among the largest sRNAs discovered and redundantly inhibit the protein CsrA 
when cell density is low.  CsrA indirectly increases the activity of the protein 
LuxO, which activates transcription of the qrr genes.  Once transcribed, Qrrs1-4, 
in conjunction with Hfq, bind the hapR transcript, destabilizing it (Lenz et al., 
2004, Lenz et al., 2005).  As HapR is an inhibitor of virulence factor production 
and biofilm formation, this results in activation of the virulence regulatory 
cascade.   
  Two other sRNAs, MicX and VrrA, affect composition of the V. cholerae 
membrane.  MicX is processed into an active molecule of 189 nucleotides and 
represses VC0972, a putative outer membrane protein, and VC0620, a 
component of a putative ABC transporter, while positively regulating VCA1041, a 
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putative phosphomannomutase.  While Hfq has been shown to stabilize this 
sRNA, presence of the protein is not necessary for binding of MicX to its targets 
(Davis & Waldor, 2007).  Similarly, the sRNA VrrA, which binds the ompA mRNA 
to block translation of the protein, does not require Hfq for its activity.  Deletion of 
vrrA results in overproduction of the porin OmpA and confers a competitive 
advantage in an infant mouse model of colonization (Song et al., 2008).   
 Small regulatory RNAs can also control metabolic functions (Richards & 
Vanderpool, 2011).  The recently described sRNA MtlS acts in cis to regulate 
mannitol uptake through the protein MtlA.  MtlS is encoded antisense to the mtlA 
gene and is hypothesized to directly base-pair with the 5ʼ untranslated region 
(UTR) of the mtlA RNA, blocking translation of the MtlA protein.  This regulation 
occurs in the presence of sugars and sugar alcohols other than mannitol; in the 
presence of mannitol, MtlS is not produced, and the mtlA mRNA can be 
translated (Mustachio et al., 2012).  Another sRNA, TarB, is transcribed under 
ToxT-inducing conditions and controls synthesis of a novel cyclic dinucleotide.  
Strains lacking TarB, which are therefore deficient in synthesis of this molecule, 
are attenuated for colonization of the suckling mouse intestine (Davies et al., 
2012).  TarB also appears to negatively regulate tcpF, a gene found on the VPI 
that encodes a secreted colonization factor (Bradley et al., 2011). It is becoming 
increasingly clear that sRNAs play important roles in the physiology and virulence 
of bacteria, particularly in V. cholerae. 
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Purpose of this Study 
 This work describes identification and characterization of TarA, a 99 
nucleotide small regulatory RNA produced by V. cholerae.  TarA is highly 
conserved among isolates of V. cholerae containing the Vibrio pathogenicity 
island and is transcribed from a promoter upstream of the gene tcpI under 
conditions in which ToxT is active.  There are no open reading frames in the 
sequence of TarA, which suggests a regulatory role for this molecule.  We 
constructed an isogenic strain of V. cholerae lacking the tarA gene and used 
microarray analysis to compare gene expression levels between this mutant and 
the wildtype strain.  Of the roughly twenty potential targets of TarA identified, only 
one, the glucose import gene ptsG, appeared to be repressed by this sRNA.  
 Chapter II of this dissertation describes the initial characterization of ptsG 
repression by TarA and explores the physiological significance of this regulation.  
We found that ptsG transcript levels drop shortly after induction of expression of 
tarA from the plasmid pHDB3.  In cells constitutively overexpressing tarA, growth 
in glucose is severely compromised due to a lack of glucose uptake.  
Additionally, we determined that TarA is stabilized by the small protein Hfq, which 
we hypothesized could catalyze base-pairing between TarA and the 5ʼ UTR of 
the ptsG transcript.  
 Chapter III of this work details further exploration of the mechanism of 
ptsG regulation by TarA.  We used biochemical approaches to directly assess 
binding between TarA and the ptsG transcript in the presence and absence of 
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Hfq.  We present evidence that TarA binds both Hfq and the ptsG transcript in 
vitro, and that Hfq is not required for base-pairing between the two RNA 
molecules.  We also determined that neither of the predicted Hfq binding sites 
found in the tarA sequence are required for binding to Hfq or the ptsG mRNA.  
We hypothesize that there may be three Hfq binding sites in the TarA molecule 
that function redundantly in binding of this protein. 
 Initial characterization of a different set of TarA targets, the nan locus, is 
detailed in Chapter IV of this study.  The genes comprising the nan locus 
appeared to be potentially activated by TarA according to our microarray 
analysis.  These genes have been studied in both E. coli and V. cholerae and 
encode proteins necessary for catabolism of sialic acid, a 9-carbon sugar.  We 
confirmed some of these findings via qRT-PCR and also began to assess the 
physiological implications of this regulation by testing for growth defects in media 
containing sialic acid.  While we have not yet been able to identify a phenotype 
for a tarA mutant in sialic acid-containing media, we hypothesize that TarA does 
regulate this locus in conjunction with the repressor NanR.   
 Finally, chapter V summarizes the findings reported in this dissertation 
and fits these discoveries into the greater picture of V. cholerae small regulatory 
RNAs and the pathogenesis of this organism.  This work has identified a 
previously unknown ToxT-activated sRNA produced by V. cholerae, TarA, which 
shares some similarity with the E. coli sRNA SgrS but is unique in several ways. 
Since our initial publication regarding TarA, two other research groups have also 
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reported finding this molecule, demonstrating that this is a key work in the field of 
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The Vibrio cholerae virulence regulatory cascade controls  
glucose uptake through activation of TarA, a small regulatory RNA 
 
 Note: A modified version of this text was previously published in Molecular 
Microbiology (Richard et al., 2010).  Figures 2.1 and 2.3 and Table 2.1 were created by 
Jeffrey H. Withey (Wayne State University), and the microarray analysis was performed 




Vibrio cholerae causes the severe diarrheal disease cholera.  A cascade of 
regulators controls expression of virulence determinants in V. cholerae at both 
transcriptional and post-transcriptional levels.  ToxT is the direct transcriptional activator 
of the major virulence genes in V. cholerae. Here we describe TarA, a highly conserved 
small regulatory RNA, whose transcription is activated by ToxT from toxboxes present 
upstream of the ToxT-activated gene tcpI.  TarA regulates ptsG, encoding a major 
glucose transporter in V. cholerae.  Cells overexpressing TarA exhibit decreased 
steady-state levels of ptsG mRNA and grow poorly in glucose-minimal media.  A mutant 
lacking the ubiquitous regulatory protein Hfq expresses diminished TarA levels, 
indicating that TarA likely interacts with Hfq to regulate gene expression.  RNAhybrid 
analysis of TarA and the putative ptsG mRNA leader suggests potential productive 
 32 
base-pairing between these two RNA molecules.  A V. cholerae mutant lacking TarA is 
compromised for infant mouse colonization in competition with wild type, suggesting a 
role in the in vivo fitness of V. cholerae.  Although somewhat functionally analogous to 
SgrS of E. coli, TarA does not encode a regulatory peptide, and its expression is 




Asiatic cholera, a severe diarrheal disease, remains a significant cause of 
morbidity and mortality in many regions of the globe (Sack et al., 2006). Cholera is 
caused by ingestion of the gram-negative, highly motile curved bacillus Vibrio cholerae 
in contaminated food or water. V. cholerae are present in many coastal areas 
worldwide; however, of the hundreds of known V. cholerae serogroups, only the O1 and 
O139 serogroups can cause cholera (Sack et al., 2004, Reidl & Klose, 2002).   
The two major V. cholerae virulence factors are the cholera toxin (CT) and the 
toxin-coregulated pilus (TCP).  Secretion of CT into the intestinal lumen by V. cholerae 
directly causes the secretory diarrhea characteristic of cholera (Gill, 1976, Lonnroth & 
Holmgren, 1973).  The genes encoding the two subunits of CT, ctxAB, are located 
within the genome of a filamentous bacteriophage, CTXΦ (Waldor & Mekalanos, 1996).  
The TCP, a type IV bundle-forming pilus, is required for intestinal colonization by V. 
cholerae and acts to initiate microcolony formation (Attridge et al., 1996, Herrington et 
al., 1988, Thelin & Taylor, 1996, Taylor et al., 1987).  The genes encoding TCP are 
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located within the Vibrio pathogenicity island (VPI), which may also be a mobile element 
but is not a bacteriophage (Manning, 1997, Karaolis et al., 1998, Rajanna et al., 2003, 
Faruque & Mekalanos, 2003).  Other putative virulence genes located within the VPI are 
coordinately regulated with ctxAB and tcp, but their roles in pathogenesis are unclear.   
Expression of genes encoding V. cholerae virulence factors is regulated by a 
cascade involving transcription activators, repressors and proteases (Matson et al., 
2007); however, the direct transcription activator of virulence genes is ToxT (Matson et 
al., 2007).  ToxT is a member of the AraC/XylS family of transcription factors (Higgins et 
al., 1992, Ogierman & Manning, 1992).  ToxT binds to a 13 bp degenerate DNA 
sequence, the toxbox, to activate transcription (Withey & DiRita, 2006), using toxboxes 
configured as direct repeats, inverted repeats, and single toxboxes to activate 
transcription of different operons (Withey & DiRita, 2006, Withey & Dirita, 2005b).  
Binding sites for ToxT have been characterized at most of the promoters it is 
known to activate (Withey & DiRita, 2006, Withey & DiRita, 2005a, Withey & Dirita, 
2005b).  An exception is the tcpI promoter, located on the VPI and encoding a putative 
methyl-accepting chemotaxis protein with an unknown role in pathogenesis (Harkey et 
al., 1994).   Our sequence analysis identified two pairs of putative toxboxes upstream of 
tcpI; one pair, in an inverted configuration, is positioned proximal to the tcpI open 
reading frame (Withey & DiRita, 2006).  The other pair, in a direct repeat configuration, 
is positioned at a site upstream of the proximal toxboxes (Figure 2.1), and thus we refer 
to them as the distal toxboxes.   Primer extension analysis performed previously by 
others identified two different start sites of tcpI transcription that would potentially 
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correspond to transcription activated by ToxT from each set of toxboxes; though when 
those studies were carried out, the toxboxes had not yet been identified (Thomas et al., 
1995, Murley et al., 2000).  We performed experiments to characterize the role of ToxT 
in transcription from both of these putative sites and have found that there are indeed 
two separate ToxT-dependent transcripts produced upstream of tcpI.  However, the 
tcpI-proximal promoter alone is responsible for transcription of tcpI itself (JHW and VJD, 





Figure 2.1.  Schematic and diagram of tcpI promoters and the surrounding 
region.  A.) Schematic. Scale bar: 0.5 centimeters represents 200 bp of DNA.  Bent 
arrows indicate putative transcriptional start sites, and long black arrows represent 
coding sequences of the known genes tcpP and tcpI.  tcpI has been shortened from 1.6 
kb for clarity.  Toxboxes, or ToxT-recognition sequences, are indicated by paired boxes. 
B.) Diagram of tcpI distal promoter, tarA, and surrounding sequences.  Bent arrows 
indicate transcriptional start sites for tcpP and tarA.  Numbers indicate position relative 
to tarA transcriptional start site.  ToxT binding sites (toxboxes) for the tcpI distal 
promoter are underlined with horizontal arrows.  The -35 and -10 elements for tarA are 
indicated by thick boxes, and thin boxes represent potential base-pairing regions in 




Here we describe a small RNA (~99 nt), which we named TarA for ToxT-
activated RNA, whose transcription from a gene located between tcpI and tcpP is 
activated by ToxT at the promoter distal to tcpI.  The TarA nucleotide sequence is highly 
conserved among both epidemic and environmental V. cholerae strains that carry the 
VPI.  We demonstrate that TarA influences glucose uptake through its effect on the 
transcript encoding the glucose transporter PtsG. 
 
Results 
ToxT activates transcription of a small non-coding RNA.   
To characterize ToxT-dependent activation of tcpI, we constructed lacZ 
fusions and assayed β–galactosidase activity in V. cholerae having either wild type toxT 
or a toxT deletion.  Our results indicated that the minimal ToxT-responsive DNA 
sequence for activating a tcpI-lacZ fusion at this tcpI-proximal promoter extended only to 
-94 relative to the proximal tcpI promoter.  Because a second separate start site for tcpI 
transcription had been previously described at -243 relative to the AUG (Murley et al., 
2000, Harkey et al., 1994), we also constructed tcpI::lacZ fusions extending to -431 
relative to the start site of transcription from the tcpI-proximal promoter to include both 
putative promoters (Figure 2.1A).  However, additional upstream DNA, even if it 
contained the putative tcpI-distal promoter, did not affect the level of β–galactosidase 
produced.  This result suggested that the distal promoter, if functional, does not read 
into tcpI under the conditions tested. 
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To determine whether the tcpI-distal promoter is functional, we created a set 
of lacZ fusions whose 3ʼ endpoints were located upstream of the tcpI-proximal promoter 
(at -173 relative to its start site and +36 relative to the distal promoter start site) and with 
5ʼ endpoints that extended to -59, -81, or -223 relative to the start of transcription from 
the distal promoter (Figure 2.1B).  Results of β–galactosidase assays using these 
constructs indicated that the tcpI-distal promoter was indeed functional and highly 
activated by ToxT (Table 2.1).  Sequence analysis identified two consensus toxboxes 
configured as a direct repeat upstream of the tcpI-distal promoter -35 box that had the 
same spacing as the toxboxes we observed at the tcpA promoter (Withey & DiRita, 
2006) (Figure 2.1B).  Deletion of one of the two toxboxes resulted in a complete loss of 
ToxT-directed transcription from the tcpI-distal promoter (Table 2.1, Figure 2.1B (-59 















Table 2.1. Nested tarA::lacZ fusion analysis.  5ʼ and 3ʼ endpoints indicate region of 
V. cholerae chromosome ligated into pTL61T plasmid.  Fusion plasmids were 
electroporated into WT O395 and an isogenic toxT strain.  Cultures were grown under 
inducing conditions for 3 hours and then tested for β-galactosidase activity, with data 
reported in Miller units.  Fold difference was determined by taking the ratio of wild type 













-223 +36 11,800 ± 500 804 ± 137 15x 
-81 +36 18,000 ± 551 436 ± 
44.8 
41x 





Downstream of the start site of transcription is a G/C rich region that could 
potentially form a stem-loop structure (boxes in Figure 2.1B), followed by a tract of T 
nucleotides on the non-template strand, suggesting the presence of a transcription 
terminator.  To determine if a small RNA product initiating at the tcpI-distal promoter 
and ending at the putative terminator is produced, we performed Northern blots on 
whole cell RNA purified from V. cholerae having a wild type or a deleted toxT gene, 
probing with an oligonucleotide complementary to the putative sRNA sequence.  A 
single RNA product of the expected size, <100 nt, was detected in the Northern 
blotting experiments (Figure 2.2).  Production of the sRNA required functional ToxT, 
was detectable beginning at three hours of growth (data not shown), continued 
through logarithmic phase, and peaked at seven hours of growth under ToxT-
inducing conditions; no TarA was detected in non-inducing conditions (Figure 2.2). 
These findings are consistent with previous observations of ToxT activity (Yu & 
DiRita, 1999).  Based on this evidence, we named this previously unknown sRNA 
“TarA” for ToxT-Activated RNA.  TarA contains a putative binding site for the 
ubiquitous regulatory protein Hfq and lacks an open reading frame; thus, its function 











Figure 2.2.  TarA is produced under ToxT-inducing conditions.  Wild type and toxT 
strains were grown under inducing and non-inducing conditions (LB pH 6.5, 30ºC and 
LB pH 8.5, 37ºC, respectively) and total RNA was collected at indicated timepoints.  
Equal amounts of RNA from each sample (as determined by OD260) were subjected to 
Northern blot analysis, using an oligonucleotide complementary to the putative sRNA 






TarA is highly conserved among V. cholerae strains.   
To determine whether TarA has homology to any other sRNA species, we 
performed searches with its sequence from the classical V. cholerae strain O395 
using both the RNAfam database and BLAST (Touzet & Perriquet, 2004).  The 
former search indicated that TarA has no homology to any known sRNA family.  
However, the latter search indicated that TarA has a very high degree of sequence 
conservation among V. cholerae (Table 2.2, Figure 2.3).  TarA sequences from eight 
different V. cholerae strains were obtained from the BLAST search; two of these are 
classical biotype V. cholerae, two are El Tor biotype V. cholerae, and four are non-
O1 V. cholerae.  The two classical strains have identical TarA sequences and the 
sequences of the two El Tor strains are also identical (Table 2.2 and Figure 2.3).  
However, the El Tor sequences have a single nucleotide insertion and two 
substitutions that differ from the classical sequences.  The non-O1 V. cholerae 
strains, commonly known as environmental V. cholerae to distinguish them from the 
O1 epidemic strains, carry the VPI but are not capable of causing cholera.  These 
environmental V. cholerae strains have TarA sequences apparently derived from the 
classical biotype or vice versa.  Three of these four non-O1 strains have TarA 
sequences identical to the classical TarA sequences; the fourth non-O1 strain has a 
single nucleotide change from the classical TarA sequences at a position that differs 
































Table 2.2.  Conservation of TarA and upstream sequences.  Asterisks indicate 












O395* Classical O1 99/99 nt 99/99 bp 
Z17561* Classical O1 99/99 nt 99/99 bp 
N16961* El Tor O1 96/99 nt 62/99 bp 
H1* El Tor O1 96/99 nt 75/99 bp 
SCE4 Environmental O8 99/99 nt 75/99 bp 
SCE200* Environmental O44 99/99 nt 91/99 bp 
SCE256 Environmental O42 99/99 nt 68/99 bp 












Figure 2.3.  Comparison of tarA sequences among V. cholerae strains.  Sequences 
from strains indicated in Table 2.2 are aligned, with bold letters indicating differences 





To determine whether the degree of TarA sequence conservation among 
different V. cholerae strains is a general feature of the VPI, we compared the 
DNA sequences 99 bp directly upstream of the tarA start site in the above strains 
to the sequence in O395.  This analysis indicated that the tarA sequence was 
preferentially conserved over the surrounding intergenic sequence (Table 2.2).  
The degree of conservation of the 99 bp directly upstream of tarA varies to a 
wide degree, even between strains that have identical tarA sequences.  For 
example, classical O395 and environmental SCE 256 have 99/99 identical base 
pairs within the tarA gene but only 68/99 identical base-pairs within the upstream 
sequence.  These upstream 99 bp include both the promoter and the two 
toxboxes that are required for expression of tarA; notably, the toxbox sequences 
are 100% conserved in every strain. We have also observed TarA expression in 
the El Tor strain N16961 under ToxT-inducing conditions (data not shown). 
These results strongly suggest that TarA conveys an evolutionary advantage to 
both environmental and epidemic V. cholerae and that its regulation by ToxT is 
highly conserved. 
 
TarA regulates ptsG mRNA levels in V. cholerae.   
To identify potential regulatory targets of TarA, we probed microarrays of the 
V. cholerae genome with RNA isolated from classical strain O395 and its tarA 
derivative.  The tarA strain features a markerless deletion of the 99 nucleotide RNA 
sequence with the promoters left intact. The whole-genome expression data were 
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analyzed using the Significance Analysis of Microarrays (SAM) program (Tusher et al., 
2001) using ≥2.0 fold differences in gene expression and a ≤1% false discovery rate 
(FDR) as cutoff values. A gene annotated as ptsG (VC2013 in the N16961 genome 
sequence) was upregulated by greater than two-fold in the tarA strain compared with 
wild type.  This is consistent with a previous microarray study (Bina et al., 2003), in 
which VC2013 RNA was shown to be upregulated in toxT mutant V. cholerae relative to 
wild type. This pattern of regulation – with VC2013 expression being negatively 
controlled by ToxT – is in contrast to that of nearly all other known ToxT-regulated 
genes, such as the toxin co-regulated pilus (tcp) and the cholera toxin (ctxAB), which 
are positively controlled by ToxT.   That ptsG may be the target of sRNA regulation in V. 
cholerae is consistent with the fact that ptsG in E. coli is also regulated by a small RNA, 
SgrS (Vanderpool & Gottesman, 2004).   
To confirm the microarray result, we used quantitative real time PCR (qRT-
PCR) comparing ptsG mRNA levels in wild type and tarA mutant V. cholerae strain 
O395.  Consistent with the microarray experiments, we observed an approximately 
three-fold increase in ptsG mRNA in mutant cells compared with wild type (Figure 2.4), 
supporting the hypothesis that TarA acts to decrease the levels of ptsG mRNA.   To be 
sure that regulation was due to the specific absence of tarA and not due to a polar effect 
on tcpI, a tcpI strain was also tested.  ptsG transcript levels in the tcpI strain closely 












Figure 2.4. Confirmation of ptsG regulation by qRT-PCR analysis.  Cultures of the 
listed strains were grown under ToxT-inducing conditions for 7 hours and total RNA was 
isolated using Trizol.  cDNA was prepared from equivalent amounts of RNA for each 
sample, and cDNA was used for SYBR Green qRT-PCR.  Numbers indicate fold change 
in transcript level between strains, calculated using the ΔΔCT method and recA 




Growth of V. cholerae in minimal glucose medium is limited in cells 
overexpressing TarA.    
In E. coli, SgrS acts to reduce ptsG mRNA levels and to limit glucose uptake 
under conditions where flux through the glycolytic pathway may be disrupted, thereby 
allowing the accumulation of potentially lethal phospho-glucoside compounds 
(Vanderpool & Gottesman, 2004).  When E. coli is grown with the glucose analogue 
alpha-methyl-glucoside (αMG), the compound is phosphorylated and taken up by PtsG, 
but phospho-αMG cannot be catabolized by the normal glucose metabolic pathway and 
therefore accumulates.  Under such conditions, sgrS expression is induced and the 
resulting degradation of ptsG mRNA reduces further uptake of αMG.  Mutants lacking 
sgrS are highly sensitive to αMG (Vanderpool & Gottesman, 2004).   We tested whether 
tarA V. cholerae exhibited enhanced sensitivity to αMG relative to wild type, which 
would be a physiological consequence of the fact that TarA regulates ptsG mRNA in V. 
cholerae.  The two strains were grown in LB supplemented with αMG in concentrations 
ranging from 1-10% weight by volume; we did not see a consistent effect of this glucose 
analogue on tarA V. cholerae at any of the concentrations tested.  
Failing to identify an αMG effect, we tested another ptsG-related hypothesis.  
We reasoned that constitutive overexpression of TarA, which would remove the RNA 
from its normal regulation by ToxT, would affect the growth physiology of V. cholerae, 
leading to diminished growth in glucose-containing minimal media if indeed ptsG mRNA 
levels are regulated by TarA.  Overexpression of TarA in LB-grown V. cholerae had a 
slight effect on culture growth rate, although the final optical density achieved by this 
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culture was close to wild type.  Growth of tarA and wild type V. cholerae carrying the 
vector alone was unaffected compared to wild type (Figure 2.5A).  However, after 
dilution from LB into minimal MOPS/0.5% glucose, the cells overexpressing TarA were 
severely deficient for continued growth and resembled the ptsG strains, while the other 
strains grew similarly after a lag phase of approximately three hours (Figure 2.5B).  The 
ptsG strain complemented with a constitutively-expressed copy of ptsG exhibited 
partially restored growth in this medium. Analysis of glucose remaining in the 
supernatants of these cultures revealed similar levels of glucose for approximately four 
hours, after which the culture overexpressing TarA and that of the ptsG mutants nearly 
stopped removing glucose from the medium while the others continued to do so (Figure 
2.5C).  Thus, the poor growth of wild type cells overexpressing TarA correlated with 







Figure 2.5. Overexpression of TarA results in severely reduced glucose uptake.  
A.) LB growth. Indicated strains were grown overnight in LB media, subcultured into 
fresh LB and grown to mid-exponential phase, then washed with PBS and diluted into 
fresh LB to OD = 0.04.  Cultures were grown in a 96-well plate at 30°C with constant 
aeration, and the OD600 was measured every 20 minutes.  Growth assays were 
performed at least three times, and a representative growth curve is shown. (B.) 
MOPS/glucose growth.  Strains were prepared as in (A), but diluted into MOPS/0.5% 
glucose instead of LB and then grown as in (A). (C.) Strains were grown overnight in LB, 
subcultured into LB and grown to mid-exponential phase, then washed and diluted into 
MOPS/0.5% glucose, and grown in flasks.  At specified timepoints, supernatants were 
collected and the glucose concentration was tested using a tetrazolium blue reducing 
sugar assay.  Calculated glucose concentrations were divided by the starting 
concentration to determine the amount of glucose remaining in the media. This 
experiment was performed three times, and a representative assay is shown.  Error 




To more carefully examine association between TarA and ptsG mRNA levels, 
we placed tarA expression under control of an IPTG-inducible promoter in pHDB3 and 
followed steady state levels of ptsG mRNA message upon TarA induction. tarA V. 
cholerae carrying this plasmid was grown in LB to mid-logarithmic levels before addition 
of IPTG to induce tarA expression.  Thirty minutes after IPTG induction, cells were 
collected, washed, resuspended in fresh media and allowed to continue growing for 
another 30 minutes.  RNA was harvested from cells at 0, 2, 10 and 30 minutes after 
addition of IPTG, and then at 10 and 30 minutes after the IPTG was washed out.  RNA 
was analyzed by Northern blotting using a probe specific for TarA or ptsG mRNA.   
Prior to induction (0 minutes) TarA was undetectable while ptsG mRNA was 
abundant.   Within two minutes after induction by IPTG, TarA became detectable and 
the amount of ptsG mRNA diminished.  This continued throughout the course of the 
experiment, with TarA expression remaining at high levels and ptsG mRNA detectable 
at levels considerably lower than those seen prior to induction (Figure 2.6).   Cells 
carrying the cloning vector alone expressed no detectable TarA and very high levels of 
ptsG mRNA.  The levels of ptsG mRNA were higher in the strain carrying only the 
cloning vector than in the cells carrying the tarA clone without induction, which could be 
due to undetectable yet functional levels of TarA being expressed even prior to addition 
of IPTG.  There is a slight decrease in ptsG mRNA levels in the vector control after thirty 
minutes of induction and ten minutes of washout (t=40 timepoint), which we attribute to 












Figure 2.6.  Induction of TarA reduces ptsG transcript levels.  Strains AR059 and 
AR060, containing an IPTG-inducible copy of TarA and an empty vector control, 
respectively, were grown overnight in LB.  Cultures were diluted 1:200 into fresh LB, 
grown until OD ~ 0.4, and stimulated with IPTG.  Thirty minutes after induction, cultures 
were washed and resuspended in fresh media lacking IPTG.  RNA was collected at 
indicated timepoints (from the start of induction) using Trizol, and equal amounts of RNA 
for each sample were subjected to Northern blot analysis.  Methylene blue staining was 
used to confirm load amounts (not shown). Blots were probed with oligonucleotides 
complementary to TarA (A) and to the ptsG transcript (B). 
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Base complementarity between TarA and the 5ʼ region of the ptsG mRNA.   
In E. coli, SgrS controls ptsG transcript levels in part by associating with the 5ʼ 
end of the ptsG mRNA and causing its degradation in a process that depends on Hfq 
and RNAse E.  (Maki et al., 2008, Wadler & Vanderpool, 2007).  We used the alignment 
prediction program RNAhybrid (http://bibiserv.techfak.uni-
bielefeld.de/rnahybrid/submission.html) to identify potential areas of complementarity 
between TarA and the leader sequence of the ptsG transcript that would be expected 
for a similar mechanism to be operating in V. cholerae. This program produced a 
structure with a favorable free energy (-40.3 kcal/mol) (Figure 2.7).  For purposes of 
comparison, we tested the potential complementarity of SgrS and the 100 bp directly 
upstream of ptsG in E. coli with the same program, which yielded a similarly-composed 
structure with a minimal free energy of -49.2 kcal/mol (data not shown).   
TarA is unstable in the absence of Hfq. Given the putative Hfq binding site 
in the TarA sequence, we hypothesized that TarA interacts with Hfq.  It is well-
established that Hfq-interacting small RNAs are markedly less stable in the absence of 
Hfq (Morita et al., 2004, Kawamoto et al., 2005, (Sledjeski et al., 2001), (Grunze et al., 
2002).  To explore a potential TarA/Hfq interaction, we assessed TarA levels by 
Northern blot analysis of RNA from wild type and hfq mutant V. cholerae. Cells were 
grown for seven hours in ToxT-inducing conditions prior to RNA isolation and blotting.   
As predicted, the hfq mutant had significantly reduced TarA RNA in comparison to the 






Figure 2.7.  Alignment of TarA and ptsG upstream sequences.  The program 
RNAhybrid (http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/welcome.html) was used to 
predict potential base-pairing between TarA and the ptsG transcript. The TarA 
sequence is shown in green and the ptsG leader sequence in red, with the 5ʼ and 3ʼ 
ends of each RNA labeled correspondingly. The 5ʼ end of TarA is unlabeled but found to 









amount:    1           0.14            .06 
 
Figure 2.8.  TarA is unstable in the absence of Hfq.  Wild type, tarA, and hfq strains 
were grown under inducing conditions (LB pH 6.5, 30ºC) and total RNA was collected 
after seven hours of growth.  Equal amounts of RNA from each sample (as determined 
by OD260) were subjected to Northern blot analysis, using an oligonucleotide 
complementary to TarA as a probe.  Methylene blue staining was used to confirm load 





Here we describe a small, non-coding regulatory RNA, TarA, whose 
transcription is directly activated by the major V. cholerae virulence activator protein 
ToxT.  Activation of a regulatory RNA by ToxT adds another level to the complex V. 
cholerae virulence regulatory cascade and contributes to our understanding of ToxT-
dependent gene activation.  Based on our previous analyses of other ToxT-activated 
genes, the promoter architecture of tarA most closely resembles that of tcpA (Withey & 
DiRita, 2006).  Furthermore, the degree of activation conferred by ToxT to the two 
genes is very similar – 41-fold for tarA and 44-fold for tcpA.  The two tarA toxboxes have 
7/7 and 6/7 of the toxbox core determinants conserved (Matson et al., 2007), the 
highest match to consensus we have observed for any operon having two toxboxes.  
However, while the degree of ToxT activation of tarA is very high, it is not higher than 
the ToxT activation of tcpA, which has a poorer match to consensus at one toxbox.  This 
suggests that the toxbox sequences may have evolved to be maximally efficient at any 
given locus, such that surrounding sequence that is not conserved in the consensus 
alignment plays a more important role than previously thought.  
TarA joins a growing list of regulatory sRNAs in Vibrio cholerae.  Four sRNAs, 
Qrr1,2,3, and 4, are involved in regulating the quorum-sensing response, together with 
Hfq protein, by negatively affecting the stability of hapR mRNA (Lenz et al., 2004).  
Another three sRNAs, CsrB,C,D, are also involved in quorum sensing; these act to 
inhibit activity of CsrA protein, which subsequently leads to expression of the Qrr sRNAs 
(Lenz et al., 2005).  Another sRNA is RyhB, which is involved in regulating iron-
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containing proteins (Davis et al., 2005).  RyhB acts with Hfq to destabilize the mRNAs 
encoding these proteins.  While many other sRNAs have been described in E. coli, very 
few of these are conserved in V. cholerae.  The exceptions are SsrA, also known as 
tmRNA, RnpB, Spf, and Ffs (Livny & Waldor, 2007).  Recently, large numbers of sRNAs 
have been identified in V. cholerae using bioinformatics and parallel sequencing 
methods (Livny et al., 2008, Vogel et al., 2003).   One of these, MtlS, previously known 
as IGR7, also contributes to regulation of carbon utilization by negatively regulating a 
mannitol transport gene, mtlA (Liu et al., 2009, Mustachio et al., 2012).  A study 
published after this work appeared in Molecular Microbiology confirmed that TarA is 
produced by V. cholerae and also identified a second ToxT-activated small RNA, TarB 
(Bradley et al., 2011).   
Our results suggest that a target of negative regulation by TarA in V. cholerae 
is ptsG, encoding a glucose transporter in the phosphotransferase system.  In E. coli, 
ptsG is negatively regulated by SgrS, an sRNA whose mechanisms of action have been 
the subject of a significant amount of research.   Expression of sgrS is activated by a 
conserved regulatory protein called SgrR, in response to glucose-phosphate stress 
(Vanderpool & Gottesman, 2004).   SgrS is a bifunctional molecule, postulated to inhibit 
PtsG through two distinct mechanisms.  One is by acting as a regulatory RNA directly 
by participating in a ternary complex with Hfq and the ptsG mRNA through specific 
base-pairing between the two RNA molecules.  The site on ptsG mRNA that is base-
paired to SgrS is in the 5ʼ end of the transcript at the Shine-Dalgarno sequence 
(Vanderpool & Gottesman, 2004), blocking translation and eventually leading to 
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degradation of ptsG mRNA through a mechanism that requires RNAse E (Maki et al., 
2008).   We think it likely that TarA also acts in a similar fashion, given the base 
complementarity between TarA and ptsG RNA, overlapping the latterʼs start codon. 
Interestingly, the V. cholerae ptsG transcript lacks a Shine-Dalgarno sequence, unlike 
that of E. coli. AU-rich sequences within a predicted unpaired region of TarA may also 
correspond to an Hfq binding domain (Figure 2.7) (Link et al., 2009).   Our observation 
that TarA is less stable in an hfq mutant lends support to our hypothesis that Hfq and 
TarA interact.  The second mechanism by which SgrS regulates PtsG is through a small 
protein, SgrT, encoded at the 5ʼ end of the same RNA that includes SgrS in E. coli and 
in a variety of other species (Wadler & Vanderpool, 2007), (Horler & Vanderpool, 2009).    
SgrT is hypothesized to act post-translationally on PtsG function (Wadler & Vanderpool, 
2007).   TarA does not have an open reading frame and is consequently much shorter 
than SgrS.  Another distinction between SgrS and TarA is that, unlike functional SgrS 
homologues in many other Gram negative bacteria (Horler & Vanderpool, 2009), a 
homologue of the SgrR regulatory protein is not found encoded next to tarA in the VPI.  
As sequence homology to sgrR was used to locate SgrS functional homologues in other 
enteric bacteria, the fact that an SgrS homologue was not predicted in Vibrio cholerae is 
not surprising. 
Unlike sgrS in E. coli, tarA expression is not controlled by the glucose-
phosphate response regulator SgrR, but rather by ToxT, the activator responsible for 
expression of the major virulence factors of V. cholerae.   The high degree of similarity 
between the tarA and tcpA toxboxes suggests that the two are expressed 
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synchronously during infection. tarA makes a slight contribution to the fitness of V. 
cholerae during infection, as competition experiments between wild type and tarA 
mutant V. cholerae in the infant mouse model resulted in a small but consistent 
colonization defect of the tarA mutant (avg. competitive index = 0.45). Cells expressing 
elevated PtsG during infection could be at a competitive disadvantage if glucose is not 
the preferred in vivo carbon source.   This hypothesis is under investigation.   An 
alternative explanation for how the link between tarA expression and virulence gene 
activation may have evolved comes from work demonstrating that V. cholerae in stool 
samples of cholera patients store glucose in the form of glycogen granules, and that 
glycogen biosynthesis genes are expressed late during infection (Schild et al., 2007).  
Of note, toxT is expressed very early in infection, and the tarA promoter most closely 
resembles that of tcpA, which is one of the first genes activated by ToxT.  Perhaps tarA 
expression by ToxT during infection, with a subsequent reduction in ptsG mRNA, 
prepares the cells for the apparent metabolic conversion to glycogen production by 
reducing the amount of glucose transported into the glycolytic pathway.        
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Materials and Methods 
 
V. cholerae strains and plasmids.   
Strains used in this work were classical V. cholerae O395, El Tor strain 
N16961, and derivatives (listed in Table 2.3).  The tarA, ptsG, and hfq strains were 
constructed from O395 and N16961 by mating with E. coli SM10λpir using the pKAS32 
suicide vector as previously described (Skorupski & Taylor, 1996).  The deletion was 
confirmed by PCR using primers flanking the gene.  Strains were grown in LB medium 
at 37° C (overnight cultures), in LB medium with a starting pH of 6.5 at 30° C (inducing 
conditions for classical strains), or under AKI conditions (inducing conditions for El Tor 
strains).  Strains were maintained in LB/20% glycerol at -70°C.  Antibiotics were used in 
the following concentrations: ampicillin: 100 µg/ml, streptomycin: 100 µg/ml and 
chloramphenicol: 30 µg/ml.  
Strains used for β-galactosidase assays were either O395 or an O395 toxT 
derivative (VJ740,(Champion et al., 1997)) carrying the respective tarA::lacZ fusion in 
plasmid pTL61T (Linn & St Pierre, 1990).  All constructs were cloned between the 
HindIII and XbaI sites of pTL61T.  For constitutive and inducible expression of TarA, 
plasmids pKK177-3RI (Opdyke et al., 2004) and pHDB3 (Ulbrandt et al., 1997) were 
used, respectively.  In pKK177-3RI, the tarA sequence alone was cloned between the 
EcoRI and HindIII sites, creating plasmid pJM292.  The tarA sequence preceded by the 
PLlacO operator sequence was cloned between the BamHI and HindIII sites of pHDB3 to 
generate pAR6.  These plasmids, and the empty vector controls, were electroporated 
into wild type O395 and N16961 (pKK177-3RI and pJM292) and the corresponding 
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DtarA strains (pHDB3 and pAR6). For ptsG complementation, the ptsG sequence 
preceded by a ribosome binding site was cloned between the EcoRI and XbaI sites of 
pUC19, generating plasmid pAR7. This plasmid and the empty vector control were then 
electroporated into N16961 ptsG.  All plasmid sequences were confirmed by the 





Strain Plasmid Genotype 
Parent 
strain Source/reference 
O395   smR   Lab collection 
JW415   O395 tarA O395 This study 
N16961   smR   Lab collection 
AR43   N16961 tarA N16961 This study 
VJ740   O395 toxT O395 
Champion et al., 
1997 
JW335 pJW184 tcpI8::lacZ O395 This study 
JW336 pJW185 tcpI9::lacZ O395 This study 
JW350 pJW186 tcpI10::lacZ O395 This study 
JW339 pJW184 
tcpI8::lacZ 
toxT VJ740 This study 
JW340 pJW185 
tcpI9::lacZ 
toxT VJ740 This study 
JW353 pJW186 
tcpI10::lacZ 
toxT VJ740 This study 
AR15   O395 hfq O395 This study 





















promoter JW415 This study 
AR74   
N16961 
ptsG N16961 This study 




control of lac 
promoter AR074 This study 
 
Table 2.3. Strains used in this study.  
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β-galactosidase assays.   
Strains were cultured overnight in LB medium at 37°C, then sub-cultured at a 
1/50 dilution into inducing medium and grown for 3 hours at 30°C with vigorous aeration.  
Bacteria were then placed on ice and chloramphenicol was added to 0.5 mg ml-1.  β-
galactosidase assays were performed using the basic procedure of Miller (Miller, 1972) 
as previously described (Withey & Dirita, 2005b). 
 
DNA manipulations.   
Plasmids were purified using the Promega Wizard Plus Miniprep kit.  
Polymerase chain reaction (PCR) was performed using Taq DNA polymerase (Roche) 
as specified by the manufacturer.  Restriction enzymes were purchased from New 
England Biolabs and used as specified by the manufacturer. 
 
Growth analysis and glucose quantification.   
Strains N16961, AR43, AR38, AR39, AR74, AR80, and AR81 were grown 
overnight in LB, then subcultured 1:100 into fresh LB and grown to mid-log phase (six 
hours).  OD600 was measured for each culture, and 1x109 bacteria of each strain were 
pelleted, washed in PBS, and resuspended to a final OD600 of 2 in PBS.  These 
suspensions were then diluted 1:50 (final OD600 = 0.04) into LB and MOPS minimal 
medium supplemented with 0.4% glucose (Neidhardt et al., 1974), and dispensed into a 
96-well plate.  The plate was incubated at 30°C with constant shaking for 8 hours in an 
Omega Polarstar plate reader, with OD600 measured every 20 minutes.   For glucose 
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quantification, cultures were prepared as described and grown in 125 mL flasks on a 
ThermoFisher orbital shaker at 37°C.  One milliliter samples were taken at 0, 4 and 8 
hours of growth.  Bacteria were pelleted, and 10-fold diluted supernatants were used in 
a tetrazolium blue reducing sugar assay as described (Jue & Lipke, 1985).  Glucose 
concentration was determined for each sample and divided by the starting concentration 
to determine the percent glucose remaining.  Assays were run in triplicate three times. 
 
Northern blots.   
Whole cell RNA was purified from O395 and VJ740 (toxT) V. cholerae grown 
in parallel under inducing and non-inducing conditions (Figure 2), from strains AR59 and 
AR60 after addition of IPTG (Figure 6), and from strains O395, AR15, and AR24 grown 
under inducing conditions (Figure 8).  At specific points (as detailed in figure legends for 
each experiment), the OD600 of each culture was read and aliquots of each culture equal 
to 1 ml of a 0.7 OD600 culture were removed.  RNA purification was performed using the 
TRIzol reagent as specified by the manufacturer (Invitrogen).  For TarA visualization, 7 
mg total RNA from each sample were separated by 8% polyacrylamide gel 
electrophoresis and transferred to an Amersham Hybond nylon membrane (GE 
Healthcare) (0.45mm) membrane with a Semi-Phor apparatus (Hoefer).  An 
oligonucleotide probe complementary to nt 12-36 of TarA was radiolabeled with γ–32P-
ATP with T4 polynucleotide kinase (New England Biolabs).  Probing conditions were as 
previously described (Sambrook, 1989).  To visualize ptsG transcript, 12.5 mg of each 
sample were run on a 1.2% agarose/formaldehyde gel and transferred to an Amersham 
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Hybond nylon membrane (GE Healthcare).  Membranes were probed with an 
oligonucleotide complementary to nt 176-208 of the ptsG transcript, labeled as above.  
 
Microarray and qRT-PCR analysis.   
Cultures of O395 and tarA strains were grown overnight and then diluted 
1:100 into LB pH 6.5 and grown at 30°C.  Once cultures reached an OD600 ~0.35, they 
were diluted 1:10 and grown until OD600 ~0.35, and 2 ml aliquots of the samples were 
harvested. Cell pellets were resuspended in TRIzol (Invitrogen) and total RNA was 
isolated according to the manufacturerʼs protocol as described previously (Yildiz et al., 
2004).  Whole genome expression analysis was performed using 70-mer oligos 
representing the open reading frames present in the V. cholerae N16961 genome.  
cDNA synthesis, microarray hybridization, and analysis of expression data were 
performed as described previously (Beyhan et al., 2006) using two biological and four 
technical replicates (for each biological replicate).  
RNA samples for qRT-PCR were DNase treated, run on an agarose gel to 
check quality, and quantified by measuring the OD260.  2.5 µg of each sample were 
treated with Moloney murine leukemia virus (M-MLV) reverse transcriptase (Invitrogen) 
according to the manufacturerʼs specifications.  For detection of transcripts, primers 
amplifying a 200-bp region in the middle of the mRNA were used with SYBR Green 
Master Mix (Stratagene) on a Stratagene MX3000P thermocycler.  Primers were 
designed using the OligoPerfect tool (Invitrogen).  Each test was performed in triplicate 
at least three times, and fold change in expression was calculated using the ΔΔCT 
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method (Pfaffl, 2001), with recA transcript levels used as controls between cDNA 
samples.    
 
Infant mouse colonization assays.  
Four-day-old CD1 mice (Charles River) were inoculated intragastrically with 
approximately 106 bacteria.  The inocula were 50:50 mixtures of the strain of interest 
(either tarA-/ lacZ+ V. cholerae or the tarA+/ lacZ+ control) and the control strain, which is 
a lacZ- O395 derivative.  Inoculated mice were incubated at 30° C for 16 hours, after 
which the mice were sacrificed and their intestines were removed and homogenized.  
Serial dilutions of the individual intestinal homogenates were plated on LB agar plates 
containing streptomycin and X-gal.  Blue and white colonies were counted after 
overnight growth at 37°C.  To determine the ratio of strains in the initial inoculum, the 
mixtures used to inoculate the mice were diluted into PBS and plated onto LB agar 
plates containing streptomycin and X-gal, and again the blue and white colonies were 
counted.  The competitive index was calculated by dividing the blue:white ratio of the 
initial inoculum by the in vivo blue:white ratio. 
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Binding interactions between TarA, Hfq, and the ptsG leader sequence  
 
Note: The cloning of the TarA internal site deletion construct detailed here was 




 TarA, a small regulatory RNA produced by the bacterium Vibrio cholerae, 
is a 99 nucleotide molecule that has been previously shown to decrease 
expression of the the glucose import gene ptsG.  In a mutant lacking tarA, ptsG 
transcript levels are approximately three-fold increased.  Transcription of tarA is 
ToxT-induced, and we hypothesize that V. cholerae uses this RNA to 
downregulate glucose uptake in the host intestine.  In order to better understand 
regulation of the ptsG gene by TarA, it is necessary to elucidate the mechanism 
of this repression.  We hypothesized that TarA makes specific base-pairing 
interactions with the 5ʼ untranslated region (UTR) of the ptsG transcript, and that 
this binding may be facilitated by the small protein Hfq.  This chapter focuses on 
efforts to test these hypotheses using electrophoretic mobility shift assays to 
monitor binding between TarA and other molecules.  We demonstrate i) that TarA 
can bind the ptsG transcript in vitro, and ii) Hfq is not required for the TarA-ptsG 
interaction, notwithstanding that Hfq protein evidently binds TarA and stabilizes 
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this molecule in vivo.  Additionally, we found that TarA contains three potential 









 The Gram-negative bacterium Vibrio cholerae, like most other bacterial 
species, produces several small regulatory RNAs that have been well 
characterized.  These RNAs regulate their targets at either the protein level, like 
the CsrB-D RNAs that are involved in quorum sensing (Lenz et al., 2005) or, 
more commonly, by interacting with the mRNA encoding their targets (Bardill et 
al., 2011, Song et al., 2008).  The latter class of sRNAs includes the Qrr1-4 
sRNAs, which redundantly regulate hapR and thus control biofilm formation and 
virulence factor production.  Recently published work has demonstrated that 
these RNAs directly bind the 5ʼ untranslated region of the hapR transcript through 
base-pairing interactions, and that this interaction is catalyzed by the small 
protein Hfq (Bardill et al., 2011).  As the Qrr sRNAs negatively regulate this gene, 
this base-pairing is presumed to recruit RNase E to degrade the transcript.   
 We previously described the ToxT-activated small regulatory RNA TarA, a 
99 nucleotide molecule that negatively regulates the gene ptsG, which encodes 
the major glucose transporter of Vibrio cholerae (Richard et al., 2010).  Our initial 
studies illustrated that Hfq stabilizes this RNA, and we hypothesized that TarA 
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directly binds the ptsG transcript in a manner similar to the Qrrs.  This would also 
be a similar mechanism to that of the E. coli sRNA SgrS, which represses ptsG in 
that bacterium.  SgrS has been extensively studied by several groups. Its 
transcription is induced under conditions of glucose-phosphate stress and upon 
expression, the sRNA base-pairs with the ptsG transcript; this binding is 
catalyzed by Hfq and results in RNase E-mediated degradation of the ptsG 
transcript (Wadler & Vanderpool, 2007, Maki et al., 2010, Vanderpool & 
Gottesman, 2004).  Mutational analysis of SgrS has defined the minimal base-
pairing interactions necessary for this regulation, and recently, the poly U tail of 
the RNA has been implicated as the required Hfq binding site (Maki et al., 2010, 
Otaka et al., 2011).  For other sRNAs, the Hfq binding site is an internal AU-rich 
sequence, demonstrating that there is not one specific binding sequence for this 
protein (Brescia et al., 2003, Zhang et al., 1998). 
 To further understand regulation of ptsG by TarA, we sought to test the 
ability of TarA to bind the ptsG transcript in vitro.  Electrophoretic mobility shift 
assays have been previously used to query RNA-RNA interactions (Bardill et al., 
2011), and we reasoned that this technique would allow us to learn more about 
several aspects of ptsG regulation through the use of various TarA mutants.  In 
this chapter, we use this experimental approach to demonstrate that TarA binds 
both Hfq and the ptsG transcript in vitro.  We also show evidence that TarA may 
possess several redundant Hfq binding sites.  Finally, while Hfq stabilizes TarA, it 
appears to be dispensable in the process of TarA-ptsG binding.      
 






TarA directly binds Hfq and the ptsG leader sequence in vitro 
To test binding of TarA to its target, ptsG, we used an electrophoretic 
mobility shift assay.  The TarA and ptsG leader sequence RNAs were generated 
via in vitro transcription, and TarA was end-labeled with 32P. The ptsG RNA 
contained the 204 nucleotides upstream of the GUG and the first 166 codons of 
the ptsG gene.  The putative transcript start site was mapped using the SoftBerry 
BPROM tool 
(http://linux1.softberry.com/berry.phtml?topic=bprom&group=programs&subgroup
=gfindb). The Vibrio cholerae Hfq protein was expressed in E. coli and purified 
using the New England Biolabs IMPACT system, which utilizes a self-cleaving 
intein tag with a chitin-binding domain (Figure 3.1).  Purified RNAs and protein 
were mixed together in native buffer, incubated at room temperature, and then 
run on a non-denaturing polyacrylamide gel. After drying, the gel was exposed to 
a storage phosphor screen and imaged using a phosphorimager. We first 
determined that in the absence of ptsG leader sequence, TarA interacted with the 











Figure 3.1 Purification of Hfq protein. The V. cholerae hfq gene was cloned 
into the vector pTYB21 and transformed into E. coli ER2566.  Cells were grown 
overnight at 16°C in the presence of 0.4 mM IPTG to induce protein expression. 
Cultures were spun down and cells were lysed by sonication. Cleared cell lysate 
was then loaded onto a column of chitin beads and allowed to empty by gravity 
flow.  The column was then washed, and cleavage of the chitin-binding tag was 
induced by addition of buffer containing DTT.  Post-cleavage, protein was eluted 
in column buffer, and elution fractions containing protein were pooled and 
concentrated.  Protein concentration was determined by spectrophotometry and 
samples were stored at -20°C. A.) Purification fractions were run on a 12.5% 
polyacrylamide gel and stained with Coomassie Brilliant Blue. B.) Eluted protein 
was electrophoresed on a 12.5% polyacrylamide gel and silver-stained using the 

























1: elution fraction 1 
 
2: spin column flow-through 
 
3: dialyzed eluate 
1: uninduced 
2: induced (pre-sonication) 
3: clarified cell extract 
4: flow-through 
5: wash 
6: beads (pre-cleavage) 
7: DTT flush 
8: beads (mid-cleavage) 
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             Hfq:                   -           -                   +          + 
   TarA (nM):              0.4         1                  0.4        1  
 
 
Figure 3.2. TarA binds the protein Hfq in vitro. TarA was transcribed in vitro 
gel purified, and end-labeled with 32P. Hfq was expressed in E. coli and purified 
using the IMPACT purification system (NEB).  Indicated concentrations of  RNA 
were mixed with 300 nM Hfq in native buffer and incubated at 25°C for 60 
minutes, then run on a nondenaturing 5% polyacrylamide gel and exposed to a 
phosphor storage screen.  Image was obtained using a Typhoon phosphorimager 
(Amersham). 
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In reaction mixtures containing only labeled TarA and the ptsG leader 
sequence, we observed a shift in mobility of labeled TarA, indicating binding 
between the species; the intensity of the shifted band increased with the 
concentration of ptsG (Figure 3.3).  When Hfq was present as well, at the highest 
concentration of ptsG leader we observed a species with mobility slightly slower 
than that of the species seen in the absence of Hfq.  We interpret this as 
comprising TarA, ptsG leader and Hfq.    In contrast, at the lowest concentrations 
of ptsG, we observed less clearly defined species with motility between that of 
TarA alone and of the putative TarA:ptsG species. This is likely a TarA:Hfq 
complex.  Additionally, samples containing Hfq appear to undergo a shift at very 
low ptsG concentrations (2.5 and 5 nM).  From this experiment, we concluded 
that TarA binds both Hfq and the ptsG transcript in vitro, and that the presence of 
Hfq may catalyze complex formation between TarA and the ptsG transcript. 




























Figure 3.3. TarA binds Hfq and the ptsG leader sequence.  TarA and a 
fragment of the ptsG transcript were in vitro transcribed and gel purified.  TarA 
was end-labeled with 32P. Hfq was expressed in E. coli and purified using the 
IMPACT purification system (NEB).  Indicated concentrations of protein and RNA 
were mixed in native buffer and incubated at 25°C for 60 minutes, then subjected 
to electrophoresis on a nondenaturing 5% polyacrylamide gel and exposed to a 
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Binding between TarA and the ptsG leader sequence is specific 
 We next sought to determine the specificity of binding between TarA and 
ptsG leader.  We reasoned that specific binding would be disrupted by addition of 
excess unlabeled TarA but not by addition of excess unlabeled, unrelated RNA.  
We repeated the gel-shift experiment with unlabeled competitor RNA (TarA and 
yeast tRNA) in 10-fold and 100-fold excess (Figure 3.4).  Again we observed an 
Hfq::TarA complex when those were the only two molecules in the reaction, and 
this complex disappeared in favor of a larger complex, presumably of 
Hfq:TarA:ptsG, when ptsG leader was added.  This tri-molecular complex was 
undetectable when 100-fold excess cold TarA, but not yeast tRNA, was added to 
the reaction mixture.  This result suggests that TarA complex formation is 
specific.     
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        ptsG leader  
   sequence (nM):               -     -   40  40   40  40  40 
            Hfq:               -     +   +   +    +    +    + 
   Cold TarA (nM):               -     -    -   10  100  -     - 
























Figure 3.4. Binding between TarA and the ptsG leader sequence is specific. 
Radioactively-labeled in vitro transcribed TarA (1 nM) was mixed with the listed 
RNA and protein amounts in native buffer and incubated at 25°C for 60 minutes. 
Unlabeled TarA was used as a competitor (cold TarA). Samples were then 
subjected to electrophoresis on a 5% native gel; the gel was then exposed to a 
storage phosphor screen and imaged with a Typhoon phosphorimager. 
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Deletion of either putative Hfq binding site does not affect binding of TarA 
to Hfq or the ptsG transcript 
 
 Previously, we had identified two putative Hfq binding sites in the 
sequence of TarA: an interior UAUUAA sequence and the poly U terminator tail 
(Richard et al., 2010). We transcribed copies of TarA lacking each of these sites 
and a double deletion construct missing both sequences.  These transcripts were 
then labeled and used in further gel-shift experiments. All three mutant constructs 
displayed binding patterns similar to wildtype for both Hfq and the ptsG leader 
sequence (Figures 3.5, 3.6, and 3.7).  We observed the same banding patterns 
as those featuring full-length TarA, suggesting that neither putative binding site 
was required for Hfq binding or for binding to the ptsG transcript.  Additionally, 
they did not appear to serve redundant functions, as the double deletion 
construct still bound Hfq and the ptsG transcript.  The labeled double deletion 
TarA sample was less radioactive than the labeled full-length TarA, explaining 
the relative faintness of the bands on the right side of the gel in Figure 3.7.  
Despite the difference in band intensities, it still seems that the shift patterns are 
similar between the samples. 
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Figure 3.5. Deletion of the internal UAUUAA site has no effect on Hfq or 
ptsG leader binding. RNA and proteins were mixed in the indicated 
concentrations with 1 nM radioactively-labeled TarA in native buffer and 
incubated at 25°C for 60 minutes.   Products were separated on a native 5% 
polyacrylamide gel and imaged with a Typhoon phosphorimager.  
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Figure 3.6. Deletion of the poly U tail does not alter Hfq or ptsG leader 
binding. Listed concentrations of ptsG leader sequence RNA and Hfq were 
mixed with 1 nM radioactively-labeled TarA in native buffer and incubated at 
25°C for 60 minutes.  Samples were then run on a 5% native polyacrylamide gel 
and imaged with a Typhoon phosphorimager. 
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Figure 3.7. Deletion of both putative Hfq binding sites does not alter Hfq or 
ptsG leader binding. Indicated concentrations of ptsG leader sequence RNA 
were mixed with 1 nM radioactively-labeled TarA and 300 nM Hfq in native buffer 
and incubated at 25°C for 60 minutes.  Samples were then run on a 5% native 
polyacrylamide gel and imaged with a Typhoon phosphorimager. 
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A.      B.  
	   	  
 
 
Figure 3.8. Predicted secondary structure of full length and double deletion 
TarA constructs. The sequences of full length TarA (A) and TarA lacking both 
the putative internal Hfq binding site and the poly U tail (B) were entered into 
Mfold (http://mfold.rna.albany.edu/?q=mfold). Pictured are the predicted folding 
patterns of these molecules.  The AUUUUG mentioned as a third potential Hfq 
binding site is found on the left side of the center loop of both constructs. 
 
 
	   86	  
Binding of a competitor RNA oligo blocks Hfq binding to the double 
deletion TarA construct but not to the full-length TarA 
 
 A third potential Hfq binding site in TarA, AUUUUG, resembles the binding 
site for Hfq in Staphylococcus aureus (AUUUUUG).  This site is accessible in the 
central loop of the predicted Mfold structure of the double deletion construct 
(Figure 3.8).  We hypothesized that this may be a binding site for V. cholerae Hfq 
as well.  To test this, we used an RNA oligo complementary to that sequence as 
a competitive inhibitor in the gel-shift assay.  This oligo features a UAAAAC 
sequence flanked by two nucleotides on either side.  As a control, we utilized an 
oligo with the same bases but out of order (AGACAGAGUCG).   
 We repeated the gel-shift assay for both the full-length and double deletion 
TarA constructs, adding in either the competitor oligo or the scrambled oligo in 
100-fold excess. While neither oligo altered Hfq binding by full-length TarA, there 
was a slight alteration of Hfq binding by the double deletion upon addition of the 
competitor oligo.  When the competitor oligo was present, we observed 
diminished intensity in the bound band, with less of this effect observed when the 
scrambled oligo was included (Figure 3.9).  However, the major gel-shifted 
species in the presence of Hfq alone (black arrow) is present in similar amounts 
at the un-shifted position (blue arrow) when either the competitor or the 
scrambled oligo are used.  As the competitor oligo affects binding of the double 
deletion TarA but not of the full-length TarA, we conclude that the third site is 
indeed a binding site for Hfq, and that it functions redundantly with one or both of 
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the previously identified sites.  More experiments will be necessary to determine 
exactly which sites are required for binding to Hfq. 
 As neither oligo appears to disrupt binding of either TarA construct to the 
ptsG leader sequence, these data also suggest that Hfq binding is not essential 
for interactions between the two RNAs.  Taking all of our data together, it seems 
likely that a major role for Hfq is to stabilize the TarA RNA. 
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            wild type TarA             double del. TarA  
    Comp. RNA (nM):      -    -   10  -    -  10  -     -    -  10   -   -  10  - 
Scramble RNA (nM):      -    -    -  10   -   -  10    -    -    -  10  -   -  10 
           ptsG (40 nM):      -    -    -    -    +  +   +    -    -    -    -   +   +  +    
           Hfq (160 nM):      -    +   +   +   +   +  +    -    +   +   +   +   +  +   





Figure 3.9. Binding of a competitor RNA oligo slightly alters Hfq binding to 
the double deletion TarA construct but not to the full-length TarA. Indicated 
concentrations of protein and RNAs were mixed with 1 nM radioactively-labeled 
TarA in native buffer and incubated at 25°C for 60 minutes. Full-length TarA was 
used for the first seven samples, while the double deletion TarA was used for the 
second set.  Samples were then separated on a 5% native polyacrylamide gel 
and imaged with a Typhoon phosphorimager.  The density of bands for samples 
containing competitor oligos were compared to those of the corresponding 









 In this chapter, we explore the mechanism of regulation of the glucose 
import gene ptsG by the small regulatory RNA TarA.  We hypothesized that this 
sRNA directly binds the 5ʼ untranslated region of the ptsG transcript by base-
pairing, and that this binding may be catalyzed by the small protein Hfq.  To test 
these hypotheses, we took a biochemical approach and analyzed binding of 
these species in vitro through electrophoretic mobility shift assays.  These 
experiments showed that radioactively-labeled wildtype TarA binds both Hfq and 
the ptsG leader sequence (likely from residue -133 to -2, as predicted by 
RNAhybrid) in vitro.  Binding of TarA to ptsG occurs in both the presence and 
absence of Hfq; in Figure 3.3, we observe binding of TarA to the ptsG leader at 
all tested ptsG concentrations. This suggests that this protein is not a required 
catalyst of the binding interaction. Taking these findings together with our 
previous result that TarA is less stable in an hfq mutant strain, we hypothesize 
that a major role for Hfq in ptsG regulation is to stabilize the TarA sRNA (Richard 
et al., 2010).  It is important to note that these experiments only provide evidence 
that binding of TarA to the ptsG transcript can occur in the absence of Hfq; it 
remains possible that binding would not lead to efficient destabilization of the 
ptsG transcript in vivo without Hfq.  We have conducted preliminary experiments 
to determine the role of Hfq in V. cholerae, testing ptsG transcript levels by qRT-
PCR in an hfq mutant compared to a wildtype strain.  These experiments showed 
a slight decrease in ptsG transcript levels compared to the wildtype but also had 
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a high standard deviation between experiments (data not shown).  The fact that 
ptsG transcript levels are not elevated in an hfq mutant grown under ToxT-
inducing conditions suggests that Hfq is not required for ptsG regulation, but 
further experiments are required to fully test this hypothesis.  
 If it is confirmed that the primary role for Hfq in ptsG regulation is to 
stabilize TarA, this would be similar to its role in conjunction with the MicX sRNA; 
Hfq has been shown to promote stability of the sRNA itself, but plays no role in 
the actual regulation of the target genes VC0972, VC0620 or VCA1041 (Davis & 
Waldor, 2007).  While similar to MicX in this way, it is notable that TarA differs 
from SgrS, its functional homolog in E. coli.  Regulation of ptsG by SgrS requires 
Hfq; in an hfq mutant strain of E. coli, SgrS-mediated destabilization of the ptsG 
transcript is not observed (Morita et al., 2004, Vanderpool & Gottesman, 2004).  
This fundamental difference in the mechanism of regulation adds to the growing 
list of dissimilarities between these two molecules that serve the same general 
function. 
 This study tested the effects of three putative binding sites for Hfq in the 
sequence of TarA.  Two of these sites (UAUUAA and AUUUUG) are internal and 
consist of AU-rich sequences, while the third is the poly-U tail of the molecule.  
We used single and double deletion constructs of TarA to assess the roles of the 
UAUUAA and poly-U sites.  We found that all three species were able to bind 
both Hfq and the ptsG transcript in a manner similar to the full-length RNA.  
These experiments, while not ruling out these sequences as Hfq binding sites, 
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suggested that if either or both of these sites bind Hfq, they are not the sole 
binding sites.  To test this hypothesis, we analyzed the AUUUUG site, which is 
one nucleotide shorter than previously characterized Hfq binding sites.  We 
tested requirement for this site by adding a competitor RNA oligo complementary 
to this sequence to the gel-shift experiments.  Addition of the oligo resulted in a  
slight disruption of binding between the double deletion TarA and Hfq, but not the 
full-length TarA and Hfq.  We interpreted this result to mean that the AUUUUG 
site is capable of binding Hfq, but that one or both of the previously identified 
sites can also bind this protein.  This suggests that there are either two or three 
Hfq binding sites present in the TarA molecule.  Further experiments with TarA 
constructs missing the AUUUUG site in combination with the other two potential 
binding sites would conclusively determine which binding sites are required for 
interaction with Hfq. 
  While this study sheds light on the role of Hfq in ptsG regulation of TarA, it 
does not address the requirement for specific base-pairing interactions between 
the two RNA molecules.  The software program RNAhybrid 
(http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/) predicts extensive base-pairing 
contacts between TarA and the ptsG transcript (Figure 2.7).  For other sRNAs, 
such as SgrS in E. coli and the Qrrs in V. cholerae, a minimal required base-
pairing region has been defined (Maki et al., 2010, Bardill et al., 2011).  We 
attempted to mutagenize TarA to study these base-pairing interactions, but were 
unsuccessful, likely due to the large number of changes introduced.  This 
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question of how TarA and the ptsG leader sequence interact is open for future 
study and would benefit from analysis by alternative methods in the future.  
Toeprint analysis to specifically determine which base-pairing interactions are 
required for binding would more clearly define the mechanism of ptsG regulation.  
Additionally, we could use lead probing to pinpoint the specific folding isoforms 
that are amenable to binding both Hfq and the ptsG leader (Lindell et al., 2002).  
These experiments would likely shed more light on the kinetics of binding 




Materials and Methods 
 
Bacterial strains and plasmids 
 
 Vibrio cholerae N16961 was used as a source of genomic DNA for 
generation of the in vitro transcription template, and Escherichia coli strains 
JM101 and ER2566 were used for cloning and protein expression, respectively.  
Strains were stored at -70°C in LB broth supplemented with 20% glycerol and 
cultured in LB broth with shaking at 37°C, except where noted.  Ampicillin was 
used at a concentration of 100 µg/ml when necessary.  The plasmid pUC19 was 
used for cloning of the TarA construct lacking the internal Hfq binding site 
(UAUUAA).  The GENEart Mutagenesis Kit (Invitrogen) was used to clone this 93 
nt sequence from a genomic DNA template.  Vibrio cholerae Hfq was cloned into 
pTYB21 (New England Biolabs) for protein expression and purification.  Plasmids 
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were purified from overnight cultures using a Qiagen Miniprep Kit, while genomic 
DNA was isolated by boiling bacterial colonies in ddH2O. 
 
In vitro transcription of TarA and the ptsG leader sequence 
 Templates for in vitro transcription were generated by PCR amplification of 
either N16961 genomic DNA (full-length and truncated TarA, ptsG) or pUC19 
carrying the TarA deletion construct.  After cleanup using a Qiagen PCR 
Purification Kit, 2 µg of template DNA was incubated with 4 mM each UTP, ATP, 
CTP, and GTP and purified T7 polymerase (generously donated by the lab of 
David Engelke) in N4 buffer containing 20 mM DTT for 4 hours at 37°C.  After 
incubation, RNA was ethanol-precipitated, resuspended in 0.3X TE and 
electrophoresed on a 6% polyacrylamide gel.  Bands were visualized by UV 
shadowing, excised and placed into 1 milliliter of elution buffer (0.3 M NaAc pH 
5.2, 1 mM EDTA, 0.1% SDS), which was then incubated overnight at room 
temperature. After elution, RNA was again ethanol-precipitated, washed, and 
resuspended in 20 µl UltraPure water and 10 µl TE pH 8.0.  RNA concentration 
and purity were determined by OD260 and OD280, respectively, using a NanoDrop 
3000 spectrophotometer. 
 
Labeling of in vitro-transcribed TarA.  
 Purified transcribed TarA was end-labeled with γ-32P-ATP using T4 
Polynucleotide Kinase (PNK, New England Biolabs).  Briefly, 30 pmol of purified 
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TarA were mixed with 4 µCi γ-32P-ATP and 1 µl T4 PNK in 1X PNK buffer in a 
total volume of 60 µl and incubated at 37°C for 60 minutes.  Labeled RNA was 
then ethanol-precipitated, washed and resuspended in 30 µl TE pH 8.0 and 
stored at  -20°C until use. 
 
Expression and purification of Hfq. 
 Vibrio cholerae hfq was cloned into the pTYB21 plasmid using the SapI 
and SacI restriction sites.  The plasmid was transformed into the expression 
strain ER2566. Cells carrying the plasmid were grown at 37°C until the OD600 
reached 0.1, then isopropyl β-D-thiogalactopyranoside (IPTG) was added to a 
final concentration of 0.4 mM and the culture was shifted to 16°C, where it was 
grown overnight with shaking.  Cells were pelleted and resuspended in lysis 
buffer (20 mM Tris pH 8.5, 500 mM NaCl, 1 mM EDTA, 0.1% Triton X-100) then 
sonicated on ice.  Lysate was cleared by centrifugation at 10,000 RPM for 30 
minutes at 4°C.  Meanwhile, a 10 ml PolyPrep Chromatograhpy Column (Bio-
Rad) was loaded with 4 ml of chitin bead slurry and equilibrated.  Cleared lysate 
was run through the column and allowed to empty by gravity flow.  The column 
was then extensively washed with column buffer (20 mM Tris pH 8.5, 500 mM 
NaCl, 1 mM EDTA).  Cleavage of the chitin-binding intein tag was induced by the 
addition of column buffer containing 50 mM DTT and incubation at room 
temperature for 36 hours.  Protein was then eluted with fresh column buffer. Eight 
hundred microliter samples were collected and stored at -20°C.  Samples were 
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tested for presence of protein by electrophoresis on a 12.5% polyacrylamide gel 
and staining with either Coomassie Brilliant Blue or an Invitrogen SilverQuest 
Staining Kit.  Eluted protein was pooled and dialyzed against fresh column buffer 
at 4°C to remove the DTT and then concentrated using an Amicon Ultra spin 
column with a 3000 Da weight cutoff.  Protein concentration was assessed by 
OD280 using a NanoDrop 3000 spectrophotometer. 
 
Electrophoretic mobility shift assays 
All binding reactions were performed in a final volume of 15 µl.  The components 
of each particular experiment are listed in the figure labels and legends. Assays 
were performed basically as in (Bardill et al., 2011). Briefly, RNAs were heated to 
70°C for 5 minutes then cooled on ice and were mixed (with protein, where 
indicated) in native buffer (20 mM Tris pH 8.0, 100 mM NH4Cl, 50 mM NaCl, 50 
mM KCl, 5% glycerol) and incubated at room temperature for 60 minutes.  After 
incubation, native loading dye was added, and the entire reaction was loaded into 
a well of a non-denaturing 5% polyacrylamide gel and electropheresed at 80V for 
6 hours 30 minutes at 4°C. Following electrophoresis, the gel was dried in a gel-
drying frame overnight and exposed to a storage phosphor screen (GE 
Healthcare).  Images were obtained with a Typhoon Trio phosphorimager 
(Amersham). 
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TarA may play a role in regulation of sialic acid catabolism 




 The bacterium Vibrio cholerae produces a ToxT-activated small regulatory 
RNA (sRNA), TarA, which negatively regulates the glucose import gene ptsG. In 
this study, we further describe the regulon of this sRNA by exploring its role in 
activation of the nan locus.  The nan locus comprises several genes involved in 
catabolism of sialic acid, a nine-carbon sugar.  Transcripts encoding the nan 
proteins were found to be present at lower levels in a tarA mutant compared to 
the wild type strain by microarray. Three of these genes were selected for further 
study by qRT-PCR; this analysis confirmed the microarray results.  However, 
deletion of tarA had no effect on utilization of sialic acid as a carbon source.  
Further study indicated that tarA expression is not induced in sialic acid-
containing media.  While TarA seems to be involved in regulation of genes for 




	   99	  
 
Introduction 
Vibrio cholerae, a Gram-negative bacterium that causes the disease 
cholera, can utilize diverse carbon sources for growth. It is endemic to the Indian 
subcontinent; in the environment, these bacteria are found in warm stagnant 
water, where their numbers are enriched during monsoon season. In this setting, 
the organisms associate with copepods, chironimid egg masses, and other 
marine species, forming biofilms on their chitinous exoskeletons (for review, see 
(Butler & Camilli, 2005)).  Chitin consists of chains of N-acetylglucosamine, a 
glucose derivative, and can be broken down and metabolized by several types of 
bacteria, including V. cholerae (Nalin et al., 1979, Veldkamp, 1952).   
Transmission of Vibrio cholerae to human hosts occurs after ingestion of 
contaminated water.  Bacteria that survive passage through the extremely acidic 
environment of the stomach progress to the small intestine, where they associate 
with mucin and rapidly divide.  Mucin is secreted by host goblet cells and 
comprises large glycoprotein complexes that are rich in sialic acid, a nine-carbon 
sugar found in both prokaryotes and eukaryotes. Presumably, V. cholerae use 
sialic acid liberated from mucin and other sugars present in the small intestine as 
carbon sources during infection.   
Sialic acid catabolism has been extensively characterized in Escherichia 
coli and has also been examined in Vibrio cholerae (Vimr & Troy, 1985, Almagro-
Moreno & Boyd, 2009). Proteins encoded by the nan locus import sialic acid 
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through the bacterial membrane and break the molecule down into fructose-6-
phosphate through a series of enzymatic reactions; fructose-6-phosphate can 
further be used by the cell for energy.  Mutants lacking any of the genes in this 
metabolic pathway are unable to grow on sialic acid media. Additionally, Vibrio 
cholerae strains missing the nanA gene are deficient for colonization of the infant 
mouse intestine when compared with a wild type strain and are outcompeted by 
the wildtype strain at a 17:1 ratio (Almagro-Moreno & Boyd, 2009).  Thus, it is 
quite likely that sialic acid cleaved from mucin is a key carbon source for V. 
cholerae in the human intestine. 
Multiplication of V. cholerae in the human gut induces secretion of cholera 
toxin (CT) by the bacterium.  This toxin stimulates efflux of chloride ions by host 
epithelial cells into the intestinal lumen.  The flow of ions into the lumen promotes 
fluid accumulation to maintain osmotic balance, and the result of this is profuse 
secretory diarrhea, which resembles rice water stool and contains up to 109 
bacteria per milliliter.  This results in shedding of the bacterium into the 
environment and further dissemination of Vibrio cholerae to new hosts. 
V. cholerae produces several small regulatory RNAs (sRNAs), which 
control quorum sensing, carbon metabolism, and outer membrane vesicle 
formation, among other functions.  Two of these RNAs, TarA and TarB, are 
transcriptionally activated by the virulence regulator ToxT, which also controls 
production of the major virulence factors of Vibrio cholerae.  In order to discover 
the regulatory targets of TarA, we performed microarray analysis of a tarA 
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deletion mutant compared to the wild type strain.  Our results suggest that the 
nan locus is activated by TarA, as in the tarA mutant, nan transcript levels were 
roughly 4 to 20-fold lower than the wild type strain.  We thus sought to determine 




TarA may enhance expression of the nan locus. 
 In order to discover potential regulatory targets of TarA, we analyzed 
microarrays to compare transcript levels in wild type and tarA mutant Vibrio 
cholerae strains.  The mutant strain, AR24, features a markerless deletion of the 
tarA sequence and is otherwise isogenic to the wild type classical strain O395. 
We used the Significance Analysis of Microarrays (SAM) program to identify 
transcripts with a ≥2.0 fold change with a 1% False Discovery Rate (FDR) 
(Tusher et al., 2001).  In this experiment, fifteen different loci, including six 
encoding genes with metabolic functions, were differentially regulated between 
the strains.  Of note, expression of several nan genes was ≥5-fold increased in 
the wild type strain compared to the tarA mutant (Table 4.1).  The genes 
comprising the nan locus have been functionally characterized by other groups 
and encode enzymes responsible for catabolism of sialic acid, a nine-carbon 
sugar found in both prokaryotes and eukaryotes (Almagro-Moreno & Boyd, 
2009).    




Gene name Fold change Gene name Fold change 
ptsG 2.72 siaM 0.16 
VC0113 0.48 nanE 0.1 
glmS 0.43 nanK 0.18 
tcpI 0.08 nagA 0.11 
lipB 0.43 VC2031 0.53 
VC1078 0.54 glnA 0.4 
VC1659 0.33 VCA0236 0.45 
nanM1 0.04 gsk-2 0.51 
nanM2 0.07 deaD 0.47 
nanA 0.12 VCA0933 0.25 
siaQ 0.3 nagB 0.47 
siaP 0.1     
  
 
Table 4.1. Microarray data. Genome expression analysis was carried out to 
compare transcript levels between wild type Vibrio cholerae and an isogenic tarA 
deletion mutant.  Whole cell RNA was isolated from cells grown under ToxT-
inducing conditions using Trizol, and microarray analysis was carried out as 
described in Materials and Methods. Shown are the fold changes in transcript 
level in the tarA mutant compared to the wild type strain. Genes found in the nan 
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 To confirm the microarray results, we tested transcript levels of several 
nan genes (nanA, nanK, and nanR) in wild type and tarA mutant strains by 
quantitative real-time polymerase chain reaction (qRT-PCR).  While the fold 
changes in transcript levels observed by qRT-PCR were not as drastic as those 
seen by microarray, the general trend of activation by TarA appears to be 
confirmed.  We found that nanA, nanK and nanR transcript levels were 0.35, 0.29 
and 0.45 times as abundant in the tarA mutant as compared to the wild type 
strain, respectively (Figure 4.1). 
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Figure 4.1. Confirmation of nan locus regulation by qRT-PCR analysis.  Cultures of 
the listed strains were grown under ToxT-inducing conditions for 7 hours and total RNA 
was isolated using Trizol.  cDNA was prepared from equivalent amounts of RNA for 
each sample, and cDNA was used for SYBR Green qRT-PCR.  Numbers indicate fold 
change in transcript level relative to the wildtype, calculated using the ΔΔCT method and 














	   105	  
 
The nan locus comprises two transcripts. 
 Many previously characterized small regulatory RNAs regulate their 
targets by base-pairing with the 5ʼ untranslated region of their transcripts.  In 
order to more accurately assess regulation of the nan locus, it was first 
necessary to determine which genes were co-transcribed.  Analysis of the 
annotated sequence suggested that the nan locus comprises two polycistronic 
transcripts. To test this, we performed reverse transcriptase polymerase chain 
reaction (RT-PCR) on cDNA synthesized from RNA isolated from wild type Vibrio 
cholerae and visualized the PCR products via agarose gel electrophoresis.  We 
reasoned that if two neighboring genes were co-transcribed, we would be able to 
amplify an intergenic fragment by RT-PCR because the transcript would include 
both of those genes.  If the genes were not co-transcribed, the PCR reaction 
would not produce a band on an agarose gel.  We designed oligonucleotide 
primers that would amplify across each of the predicted intergenic regions and 
used these for the RT-PCR reactions.  As a negative control, we designed 
primers that would amplify across the intergenic region between the two 
presumed transcripts.  After visualization by ethidium bromide staining of agarose 
gels, we concluded that the predicted transcript organization was correct (Figure 











                A         B         C         D         E       F                  G      H        I
 
 
B)           A        B      C       D        E       F            G           H           I 
  
Figure 4.2. The nan locus comprises two transcripts. A) Schematic drawing 
of nan locus. Letters indicate junctions queried by RT-PCR. B.) PCR-amplified 
intergenic regions.  Empty lanes in between bands correspond to identical 
samples run without reverse transcriptase to ensure that RNA samples were free 
of DNA contamination. Experiments performed by Kaitlin Flynn. 
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Deletion of tarA has no effect on growth in sialic acid-containing media. 
Based on the observation that TarA appears to increase expression of the 
nan genes, we hypothesized that the consequence of decreased nan transcript 
levels would be growth deficiency in media with sialic acid as a sole carbon 
source. We tested growth in both liquid and solid MOPS minimal media 
containing sialic acid, N-acetylglucosamine (which may be metabolized by nag 
genes found adjacent to the nan genes), and mucin as sole carbon sources.  In 
all media tested, the tarA mutant grew as well as the wild type, reaching similar 
final optical densities in the same amount of time (Figures 4.3 and 4.4).  On solid 
media, the mutant strain formed colonies similar in size and number to the wild 
type (data not shown).    
  
 





Figure 4.3. Deletion of tarA has no effect on growth in media containing 
sialic acid as a carbon source. A.) Sialic acid growth. Wild type (N16961) and 
tarA strains of Vibrio cholerae were grown overnight in LB at 37°C with shaking, 
then subcultured 1:100 into fresh LB.  Once this culture reached mid-log phase, 
cells were spun down, washed, and resuspended in MOPS minimal media 
supplemented with 0.1% sialic acid. Cultures were then dispensed into a 96-well 
plate and grown for 14 hours in a Polarstar Omega plate reader, with OD600 
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Figure 4.4. Deletion of tarA has no effect on growth in media containing N-
acetylglucosamine as a carbon source. Cultures were prepared as in Figure 
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tarA expression is not induced by the presence of sialic acid. 
 tarA expression is induced under conditions in which the virulence 
activator ToxT is active.  For the classical strains of Vibrio cholerae analyzed, 
these conditions consist of growth at 30°C in LB pH 6.5. Under ToxT-inhibiting 
conditions (LB pH 8.5 at 37°C), no TarA is observed by Northern blot. As TarA 
appears to either activate transcription of the nan locus or stabilize the nan 
transcripts, we reasoned that tarA would be induced in the presence of sialic 
acid.  To test this, we grew wild type and tarA mutant Vibrio cholerae in LB until 
late log phase, and then washed and resuspended the cells in MOPS minimal 
media supplemented with 0.1% sialic acid. We isolated total RNA after thirty 
minutes of incubation in this media, ran the RNA samples on a polyacrylamide 
gel, transferred to a nylon membrane, and then probed with radioactively labeled 
probe complementary to the TarA sequence.  We did not observe any bands for 
TarA in the lanes corresponding to the sialic acid-grown samples (Figure 4.5), 
leading us to conclude that the presence of sialic acid does not induce TarA 
expression. 
 






 LB                SA 
                                        +       WT    tarA     WT     tarA 
 
Figure 4.5. TarA is not produced in response to sialic acid. Northern blot 
analyzing tarA expression. Wild type and tarA mutant classical Vibrio cholerae 
were grown overnight in LB at 37°C, then subcultured into fresh LB and grown to 
mid-log phase.  Cells were then spun down, washed and resuspended in LB or 
MOPS minimal media supplemented with 0.1% sialic acid and incubated at 37°C 
for thirty minutes. Whole cell RNA was isolated using Trizol, and Northern blot 
analysis was conducted as detailed in Materials and Methods.  Wildtype cells 
grown under ToxT-inducing conditions were used as a positive control. 
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Discussion 
 In this study, we sought to further examine the regulon of the small 
regulatory RNA TarA, which is produced by Vibrio cholerae. Based on data from 
a microarray experiment comparing wild type and tarA mutant bacteria, we 
hypothesized that TarA activates expression of the nan locus.  We confirmed 
positive regulation of three of these genes by quantitative real-time PCR, though 
the microarray indicated a stronger effect of TarA than the qRT-PCR did.  Levels 
of the nanA transcript in the wild type were 8.33 fold higher than in the tarA strain 
by microarray, while the qRT-PCR data indicated a more modest 2.8 fold change.  
Similar results were observed for the nanK transcript as well.  The results for 
nanR, the putative repressor of this locus, agreed between experiments (2.1 fold 
by microarray vs. 2.2 fold by qRT-PCR).   
 We reasoned that if TarA is a positive regulator of the nan locus, it is likely 
that deletion of tarA from the genome and the resulting lower levels of nan 
transcripts would render the bacteria less well-equipped for sialic acid 
metabolism.  To test this, we grew both mutant and wild type strains in minimal 
media containing sialic acid as the sole carbon source.  We were surprised to 
discover that the tarA mutant grew equally well in this media, reaching the same 
final optical density at the same rate as the wild type strain.  We also tested 
growth of these strains on solid media containing mucin, which contains sialic 
acid, and again saw no effect for the tarA deletion mutant. Finally, we tested 
media supplemented with N-acetylglucosamine, as the nagA gene found at the 
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nan locus encodes N-acetylglucosamine-6-phosphate deacetylase, a protein 
involved in catabolism of this sugar (Yamano et al., 1997).  We saw no growth 
defect for the tarA mutant in this media. 
 It is important to note that prior to dilution in minimal media for these 
growth experiments, cells were grown in plain LB at 37°C until they reached mid-
log phase.  For the El Tor strains used in this experiment, these conditions are 
not virulence-inducing, and TarA is not expressed.  Thus, if the presence of sialic 
acid induced TarA production, we would expect to see a defect for the tarA 
mutant strain with regards to sialic acid growth.  On the other hand, if sialic acid 
does not induce expression of TarA, the tarA mutant would behave like the wild 
type when grown in sialic acid media.  Based on the phenotypes (or lack thereof) 
seen in sialic acid and mucin-containing media, we predicted that TarA 
expression would not be induced by the presence of sialic acid.  We already 
established that TarA gene expression is under ToxT control (Richard et al., 
2010) and, if it were also subject to control by sialic acid we would be interested 
in exploring the mechanisms of that.  To examine this, we grew cells in LB to 
mid-log phase, then washed and resuspended them in MOPS media containing 
sialic acid, collecting whole cell RNA samples after thirty minutes of incubation in 
this media.  We tested for TarA expression by Northern blot analysis and found 
that no detectable TarA was produced after sialic acid exposure.   
 Taking the growth phenotypes and the Northern blot data together, the 
fact that the presence of sialic acid does not induce TarA expression seems to 
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explain the lack of growth phenotypes observed in the different media tested.  
Additionally, during colonization of the human intestine, TarA would already be 
expressed because ToxT is active under those conditions, so there would be no 
need for control by sialic acid in this environment.  Repeating these experiments 
with pre-growth in AKI – the conditions that stimulate toxT expression in El Tor V. 
cholerae – could be instructive. This would maximize TarA levels in the wild type 
strain prior to dilution into sialic acid media, allowing for the biggest difference in 
growth phenotypes to be observed.  We predict that growth of cells in AKI 
conditions prior to exposure to sialic acid will cause the wild type strain to grow 
more quickly in MOPS/sialic acid than those grown in LB, as they will be pre-
loaded with TarA and consequently will have enhanced expression of the nan 
genes.  Additionally, these experiments could be performed with the plasmid-
borne inducible tarA used in the ptsG regulation experiments.  
 The experiments detailed here suggest that further investigation into the 
exact regulatory role of TarA on the nan locus is certainly warranted.  Among the 
proteins encoded by the nan locus is NanR, a putative repressor of this set of 
genes.  While the role of NanR in regulation of sialic acid metabolism has been 
well studied in E. coli, its role in V. cholerae is less established.  In E. coli, NanR 
binds to the nanA promoter in the absence of sialic acid, blocking transcription of 
nanA and the downstream genes nanT, nanE, and nanK.  When sialic acid is 
present, binding of this molecule to NanR relieves repression at this locus 
(Kalivoda et al., 2003).  This type of regulation is presumed for Vibrio cholerae 
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but has not been directly shown. Additionally, the nan genes of V. cholerae are 
organized differently than those of E. coli: they make up two divergent transcripts 
separated by an intergenic region of only 31 bases.  Future experiments should 
explore whether NanR binds this region in the presence and absence of sialic 
acid.   
 Based on our gene expression analysis, nanR transcripts are 
approximately 2-fold decreased in a tarA deletion mutant, while transcript levels 
for the other genes at that locus are more strongly down-regulated.  This 
suggests that TarA induces or de-represses the putative repressor of this locus, 
which would ultimately lead to down-regulation of the nan genes. As this scenario 
does not agree with our observations, we favor a model in which TarA regulates 
the nan locus directly, and that there are simply two different mechanisms by 
which these genes are controlled (Figure 4.6).  In the environment, where there is 
presumably little sialic acid present and TarA is not expressed, NanR may bind 
the intergenic region between the two nan transcripts, preventing transcription of 
the entire set of genes.  Once introduced to the host, virulence-inducing 
conditions prompt activation of ToxT and expression of TarA.  TarA accumulates 
to high levels in time for passage to the small intestine, where free sialic acid 
binds NanR, removing it from the DNA it is bound to and allowing for transcription 
of the nan genes.  TarA could then potentially bind the nan transcripts and either 
stabilize them or conformationally change the upstream untranslated region to 
allow for ribosome binding.  As nanR is co-transcribed with the other nan genes, 
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this scenario would explain the apparently contradictory microarray results 
mentioned previously.    
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Figure 4.6. Model of nan regulation by TarA and NanR.
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   This study has shown that the small RNA TarA likely plays a role in 
regulation of sialic acid metabolism.  To our knowledge, control of this process by 
a small RNA has not been described in any other bacterial species.  Further 
characterization of this locus and its regulation by TarA has the potential to define 
a new paradigm in the study of bacterial physiology.  
 
 
Materials and Methods 
 
Bacterial strains and growth conditions.   
The experiments detailed in this study utilized the classical strain O395, 
the El Tor strain N16961, and their derivatives AR24 and AR43, which are 
markerless tarA deletion mutants in those backgrounds, respectively.  Creation of 
these strains is detailed in the Materials and Methods section of Chapter II.  
Strains were stored at -70°C in Luria-Bertani (LB) broth supplemented with 20% 
glycerol, and were streaked on solid LB agar supplemented with 100 µg/ml 
streptomycin.  For routine growth, bacteria were cultured in LB broth at 37°C with 
aeration at 200 rpm.  For experiments requiring ToxT-inducing conditions 
(classical biotype), cells were grown in LB pH 6.5 at 30°C with shaking.  Growth 
under ToxT-inhibiting conditions utilized LB pH 8.5 at 37°C.  
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RNA isolation for microarray analysis and qRT-PCR.  
Cultures of O395 and tarA strains were grown overnight and then diluted 
1:100 into LB pH 6.5 and grown at 30°C.  Once cultures reached an OD600 ~0.35, they 
were diluted 1:10 and grown until OD600 ~0.35, and 2 ml aliquots of the samples were 
harvested. Cell pellets were resuspended in TRIzol (Invitrogen) and total RNA was 
isolated according to the manufacturerʼs protocol as described previously (Yildiz et al., 
2004).  Whole genome expression analysis was performed using 70-mer oligos 
representing the open reading frames present in the V. cholerae N16961 genome.  
cDNA synthesis, microarray hybridization, and analysis of expression data were 
performed as described previously (Beyhan et al., 2006) using two biological and four 
technical replicates (for each biological replicate).  
RNA samples for qRT-PCR were treated with DNase I (Roche) according to 
manufacturerʼs instructions, run on an agarose gel to check quality, and quantified by 
measuring the OD260.  2.5 µg of each sample were treated with Moloney murine 
leukemia virus (M-MLV) reverse transcriptase (Invitrogen) according to the 
manufacturerʼs specifications.   
 
Quantitative Real-Time PCR (qRT-PCR) and Reverse Transcriptase PCR (RT-PCR).  
For detection of transcripts by qRT-PCR, primers amplifying a 200-bp region 
in the middle of the mRNA were used with SYBR Green Master Mix (Stratagene) on an 
ABI 7500FAST thermocycler.  Primers were designed using the OligoPerfect tool 
(Invitrogen).  Each test was performed in triplicate at least three times, and fold change 
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in expression was calculated using the ΔΔCT method (Pfaffl, 2001), with recA transcript 
levels used as controls between cDNA samples.   For amplification across intergenic 
regions by RT-PCR, prepared cDNA was amplified by standard PCR using Taq 
polymerase (Invitrogen) and primers that would amplify only the intergenic region of 
interest.  Five microliters of each 50 microliter reaction were then run on a 1% agarose 
gel, and bands were visualized after ethidium bromide staining. 
  
Analysis of growth in sialic acid-containing media.   
Strains N16961 and AR43 were grown overnight in LB, then diluted 1:100 into 
fresh LB and grown to mid-log phase (~six hours).  OD600 was measured for each 
culture, and 1x109 bacteria of each strain were pelleted, washed in PBS, and 
resuspended to a final OD600 of 2 in PBS.  These suspensions were then diluted 1:50 
(final OD600 = 0.04) into LB and MOPS minimal medium supplemented with 0.1% sialic 
acid or N-acetylglucosamine (Neidhardt et al., 1974), and dispensed into a 96-well plate.  
The plate was incubated at 30°C with constant shaking for 14 hours in an Omega 
Polarstar plate reader, with OD600 measured every 20 minutes.  Each experiment was 
run in triplicate three times.   
 
Northern blots.  
O395 and AR24 (tarA) V. cholerae were grown overnight in LB with shaking at 37°C 
and then subcultured into fresh LB broth and grown at 37°C with shaking.  Once the 
cultures reached mid-log phase (OD600 ~0.5), cells were enumerated, spun down, 
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washed with PBS, and resuspended in either MOPS minimal media supplemented with 
0.1% sialic acid or fresh LB.  These cultures were then incubated at 37°C with shaking 
for 30 minutes. Whole cell RNA was then purified from roughly 1.5 x 109 cells from each 
culture.  RNA purification was performed using the TRIzol reagent as specified by the 
manufacturer (Invitrogen).  For TarA visualization, 7 µg total RNA from each sample 
were separated by 8% polyacrylamide gel electrophoresis and transferred to an 
Amersham Hybond nylon membrane (GE Healthcare) (0.45 mm) membrane with a 
Semi-Phor apparatus (Hoefer).  An oligonucleotide probe complementary to nt 12-36 of 
TarA was radiolabeled with γ–32P-ATP (Perkin-Elmer) with T4 polynucleotide kinase 
(New England Biolabs).  Probing conditions were as previously described (Sambrook, 
1989).  
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 This dissertation details the discovery and characterization of TarA, a 
small regulatory RNA produced by the bacterium Vibrio cholerae.  The goal of the 
study was to determine the function and regulatory targets of this small RNA after 
its initial discovery by a former postdoctoral fellow in the lab, Dr. Jeffrey Withey.  
Our findings are discussed in detail below. 
 
TarA is a conserved, ToxT-regulated small RNA 
 The small RNA TarA is transcribed from a promoter upstream of the gene 
tcpI, which is located on the Vibrio pathogenicity island (VPI) and is divergently 
transcribed from the gene tcpP.  Identified during a study of toxboxes, or ToxT 
recognition sequences, this RNA is 99 nucleotides in length and is transcribed 
under conditions in which the protein ToxT is active (Figure 2.2).  Its sequence is 
highly conserved among Vibrio cholerae isolates that possess the VPI (Table 
2.2).  TarA is readily detectable by northern blot after three hours of growth under 
virulence-inducing conditions but is not seen in cells lacking toxT or those grown 
under inhibiting conditions.  We hypothesized that this RNA plays a regulatory 
role in Vibrio cholerae because it does not contain any open reading frames, is 
	   124	  
highly conserved, and possesses putative binding sites for the small RNA-
binding protein Hfq. 
 
TarA represses the glucose import gene ptsG 
 To identify potential regulatory targets of TarA, we performed microarray 
analysis comparing transcript levels in a tarA deletion mutant to a wild type 
strain.  Of the 23 genes identified, only one, ptsG, was present at levels higher 
than our two-fold cutoff in the tarA mutant than the wild type strain, suggesting 
that it is negatively regulated by TarA.  Quantitative real-time PCR (qRT-PCR) 
confirmed this, demonstrating a 2.7-fold increase in transcript levels for the tarA 
mutant relative to the wild type. We reasoned that in a strain overexpressing 
TarA, ptsG would be expressed at lower levels, and growth in glucose would be 
hampered by inefficient uptake of the sugar from the media.  Upon testing this 
hypothesis, we observed that growth in glucose is severely attenuated in this 
strain while growth in LB is unaffected (Figure 2.5).   
 
Regulation of ptsG by TarA is likely due to base-pairing between TarA and 
the ptsG leader sequence   
  
 Many bacterial sRNAs function in trans by binding the mRNA encoding 
their target gene.  This interaction is in many cases catalyzed by the protein Hfq, 
which can bind both sRNAs and their targets.  Formation of this ternary complex 
can recruit either RNase E or the ribosome to degrade the transcript or promote 
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translation, respectively.  As TarA is stabilized by Hfq (Figure 2.8) and negatively 
regulates ptsG, we hypothesized that it base-pairs upstream of the GUG of the 
ptsG transcript with the help of Hfq.  Using electrophoretic mobility shift assays 
(EMSA), we found that TarA binds the ptsG leader sequence in vitro 
independently of Hfq (Figure 3.3).  TarA does bind purified Hfq in vitro (Figure 
3.2), but presence of this protein is not required for TarA-ptsG binding.  We 
hypothesize that a major role of Hfq in ptsG regulation is to stabilize TarA and 
protect it from degradation by RNases in the cell.  To further elucidate this, we 
wanted to determine the exact binding site for the Hfq protein on TarA.  We 
cloned deletion constructs of TarA that lacked one or both of two putative Hfq 
binding sites, an internal UAUUAA sequence and the poly U terminator tail.  
When analyzed by EMSA, all three of these constructs bound Hfq and the ptsG 
leader sequence as efficiently as the full-length molecule (Figures 3.5, 3.6 and 
3.7).  Preliminary work using a competitor RNA oligo complementary to a third 
potential binding site, AUUUUG, indicated that this site appears to be important 
for Hfq, and that it likely functions redundantly with one or both of the other sites 
(Figure 3.8).   
 
Future perspectives on ptsG regulation 
 While this study provides many details about the mechanism and 
physiological consequences of ptsG repression by TarA, it also prompts several 
new questions.  As tarA expression is induced by ToxT, which is activated early 
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in infection upon access to the gastrointestinal tract of the host, it follows that 
ptsG expression is repressed in the human small intestine, the site of 
colonization.  This seems counterintuitive at the outset, as glucose is one of the 
easiest sugars to metabolize.  However, glucose is actively absorbed through the 
intestinal epithelium, and thus free glucose may be limited in this environment.  
Several studies have found that expression of glucose transporters in the small 
intestine is increased in cholera patients and infected animals (Flach et al., 2004, 
Schiller et al., 1997), and that the ability of these transporters to take up glucose 
is unaffected by cholera infection (Rohde & Cash, 1973). As glucose and sodium 
are co-transported in the intestine, this is likely an attempt by the host to reclaim 
ions from the intestinal lumen, and would result in lower local glucose 
concentrations.  Repression of ptsG by TarA may simply shift the bacterium from 
uptake of glucose to usage of a more abundant carbon source.  As ptsG has 
been shown to indirectly negatively regulate biofilm production, this could result 
in increased planktonic growth in the intestine. 
 Additionally, studies from the Camilli laboratory have shown that vibrios 
actively store sugars in the form of glycogen prior to expulsion from the host; this 
provides nutrient stores once the bacteria are released into the environment, 
which is nutrient-poor (Bourassa & Camilli, 2009).  In V. cholerae, glycogen is 
continuously synthesized by the enzyme GlgC1 and degraded by GlgX.  Under 
nitrogen-limiting conditions, GlgX is repressed, leading to accumulation of 
glycogen.  Preliminary evidence has shown that another glycogen synthesis 
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gene, glgC2, is induced by RpoS, which is active during late stages of infection, 
suggesting that V. cholerae both increases glycogen production and decreases 
glycogen catabolism late in infection.  Temporally, repression of ptsG by TarA 
may coincide with the final stages of glycogen storage. In this scenario, the 
bacteria would down-regulate glucose uptake because they have stockpiled 
enough nutrients for the next stage of the infectious cycle.  Future experiments 
exploring the temporal expression of tarA and ptsG in an animal model of 
infection would likely shed light on this intriguing question.   
 This work also provides some insight into the mechanism of ptsG 
regulation by TarA and how this sRNA is different from its functional homolog in 
E. coli, SgrS.  Like SgrS, TarA binds the 5ʼ untranslated region of its target 
mRNA, and induced expression of the sRNA leads to destabilization of the ptsG 
transcript.  However, tarA expression is induced by the virulence regulator ToxT, 
while sgrS is regulated by the protein SgrR and is expressed under conditions of 
stress induced by glucose-phosphate accumulation. Repression of ptsG by SgrS 
requires Hfq, which binds to a single site on the sRNA, the poly U tail.  
Conversely, TarA can bind the ptsG leader sequence in the absence of Hfq, and 
ptsG transcript levels in an hfq mutant are not increased compared to the wild 
type strain.  Hfq does appear to be important for stabilization of TarA, but unlike 
SgrS, TarA possesses multiple redundant binding sites for Hfq.     
 An especially interesting area for future study is the kinetics of binding 
between TarA, Hfq and the ptsG transcript.  TarA is predicted to fold into one 
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particular secondary structure by the prediction software Mfold (Figure 3.8). Our 
EMSA analysis suggests that there are several folding isoforms present under 
non-denaturing conditions, based on the multiple radioactive bands observed 
with unbound TarA.  Furthermore, it appears that different folding isoforms are 
more favorable for binding Hfq and the ptsG transcript. In lanes where a shift due 
to Hfq binding is observed, we see depletion of one unbound TarA band, 
whereas in lanes where TarA is binding ptsG, a different TarA band diminishes in 
signal as binding increases.  This phenomenon is well illustrated on the right side 
of Figure 3.5.  Future experiments to determine the exact folding conformations 
adapted by TarA and the ability of each of these isoforms to bind both Hfq and 
the ptsG transcript will further elucidate the mechanism of binding between these 
species. 
 
TarA regulates the nan locus in Vibrio cholerae. 
 Chapter IV of this study examines another set of potential TarA targets, 
the nan locus. The genes of this locus comprise two divergent transcripts and 
encode the proteins required for sialic acid catabolism in V. cholerae.  In a tarA 
mutant strain, transcript levels for these genes are 3 to 20-fold lower than the wild 
type strain, suggesting that TarA positively regulates their expression.  We 
hypothesized that a tarA mutant would be deficient for growth in minimal media 
containing sialic acid as a sole carbon source due to lowered levels of nan gene 
expression.  However, the mutant strain grew just as well as wild type in this 
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media.  Upon further examination, we found that the conditions under which we 
grew these cells did not induce tarA expression, which explains why we did not 
observe a difference between the wild type and tarA mutant strains.   
 Additionally, the protein NanR is encoded at this locus and is a putative 
repressor of these genes that has been well characterized in E. coli but is less 
well studied in V. cholerae. In E. coli, this protein binds the nanA promoter when 
sialic acid is not present, blocking transcription of nanA and its downstream 
neighbors.  In media containing sialic acid, NanR binds this carbohydrate and no 
longer blocks the nan promoter (Kalivoda et al., 2003).  We propose that both 
TarA and NanR serve to regulate the nan genes in Vibrio cholerae, allowing the 
bacterium to most efficiently adapt to changing nutrient conditions in the 
environment and the host.  When little to no sialic acid is present, such as during 
growth in the environment outside of human hosts, NanR likely binds the 
intergenic region between the two nan transcripts on the chromosome of V. 
cholerae, blocking transcription.  Once the bacterium is ingested by the host, 
ToxT activates expression of tarA as V. cholerae passes through the 
gastrointestinal tract.  The intestinal lumen is rich in mucin, which contains sialic 
acid that can be cleaved off by the V. cholerae protein NanH.  In this 
environment, sialic acid could then bind NanR and relieve repression of the nan 
genes.  TarA would be present at high levels at this point, and could serve to 
stabilize nan transcripts and/or promote translation of these transcripts.  In this 
way, TarA and NanR could coordinately regulate expression of these genes to 
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best respond to environmental conditions.  Further study is required to test these 




 This work describes the ToxT-activated RNA TarA and adds a new 
member to the existing repertoire of small regulatory RNAs in Vibrio cholerae.  
We show that this molecule regulates carbon metabolism in this organism by 
repressing the glucose transporter PtsG and activating the nan locus, which 
encodes genes involved in sialic acid metabolism.  TarA serves as a link 
between the virulence regulatory cascade and metabolism, allowing the 
bacterium to adapt to the changing nutrient conditions it encounters as it cycles 
between the environment and its niche in the host, the distal small intestine.  
These discoveries enrich our knowledge of Vibrio cholerae and small regulatory 
RNAs in general, and contribute to a deeper overall understanding of bacterial 
pathogenesis.   
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